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SUMMARY 
Coronary Heart Disease (CHD) is the commonest cause of premature death in men and women in 
Scotland. Research has suggested that a significant proportion of incident CHD is attributable to 
modifiable risk factors such as level of physical activity, diet and smoking. This recognition that CHD is a 
largely preventable disease has focused health policy, both in the UK and elsewhere, on prevention 
strategies.  
There is well established evidence of a socioeconomic gradient in CHD; where those of lowest 
socioeconomic position (SEP) experience the highest CHD burden and greatest exposure to 
cardiovascular risk factors. This presents distinct challenges for effective primary prevention (defined as 
the prevention of new-onset CHD) and secondary prevention (defined as the prevention of recurrent 
coronary events in patients with established CHD) of the disease. A key consideration in the 
implementation of CHD preventative strategies is thus the measure of SEP used in the allocation of 
preventative resources.  
This study will investigate the predictive validity of Council Tax Valuation Banding (CTVB) in 
identifying high-risk sub-groups within both CHD primary and secondary prevention populations. CTVB 
is worthy of consideration as a marker of SEP in this context as it appears to have several appealing 
characteristics appropriate for use in CHD prevention. CTVB is based on the property value; theoretically 
reflecting both individual material circumstance and to an extent geographical area characteristics. 
Furthermore CTVB is objective, uncomplicated, universally available and sensitive to the household 
level. This study originated from an interest in developing practical and applicable methods of identifying 
highest risk individuals within CHD prevention populations. Gaps in existing research support a need for 
this.  
Firstly a cohort of just under 2,000 men and women, aged between 45-60 years who participated in the 
Have a Heart Paisley (HaHP) CHD Primary Prevention Programme was examined. These individuals 
were enrolled in 2006 and underwent comprehensive cardiovascular risk screening. Secondly, in 2009, 
the HaHP Chronic Disease Register (CDR) was used to pool Secondary Prevention primary care data for 
just over 3,000 men and women, of all ages with established CHD.  
Socioeconomic patterning of risk factors and absolute risk was examined in the primary prevention 
population. Socioeconomic inequalities were examined in risk-factor monitoring and therapies 
prescribing in the secondary prevention population. SEP for analyses in both populations was measured 
using the Scottish Index of Multiple Deprivation (SIMD) and CTVB- which was supplied by the  
 
3
Renfrewshire Joint Valuation Board. Both measures of SEP were linked to these data using address 
information and postcodes.  
The findings of this study demonstrate some potential for the use of CTVB as a surrogate marker of SEP 
in health research and cardiovascular preventative strategies. But that further research on this matter is 
required. CTVB showed significant association with few classical cardiovascular risk factors in the 
primary prevention population; body mass index in females, high-density lipoproteins (HDL) cholesterol 
in females, and rates of current smokers in both males and females (age and age-squared adjusted). 
However all associations with the exception of rates of current smokers (both males and females) became 
insignificant when SIMD was added into the statistical modelling. CTVB displayed association with 
Framingham risk scores in both men and women (age and age-squared adjusted) however added 
independent predictive power in men only.  
The associations between SEP (as measured by CTVB) and classical risk factors in the present study are 
generally weaker than the literature reviewed using established measures of SEP. Particularly striking is 
the insignificant socioeconomic variance in blood pressure levels when using CTVB, which is at odds 
with the overwhelming majority of literature in this field to date. Aside from the CTVB analyses, in 
general the analysis undertaken adds to existing literature; re-enforcing the existence of socioeconomic 
inequalities in classical risk factors and absolute risk in an asymptomatic population. 
When examining the secondary prevention population, significant socioeconomic (using CTVB as a 
measure of SEP) variance was identified in risk-factor monitoring and in some therapies prescribing. The 
analyses demonstrates that the removal of “exception reporting” from the Quality Outcomes Framework 
(QOF) records reveals some important inequalities in care and treatment within an established CHD 
population. The analyses did demonstrate that overall rates of risk factor monitoring and therapies 
prescribing have risen markedly over the past decade, especially post introduction of the QOF. These 
findings have important implications for the delivery of the QOF in Scotland and for Secondary 
Prevention of CHD in general. 
Considerable methodological difficulty was encountered when using CTVB as a surrogate marker of SEP. 
Data linkage based on address and postcode data proved problematic, notable proportions within each 
population required matching “by hand” which proved time consuming. Furthermore use of CTVB in this 
study identified significant potential to misclassify the SEP of individuals who are renting properties; 
particularly homes of multiple occupation. Additionally the marked rise in housing price over the past two 
decades in the UK may further compromise CTVB’s accuracy as a measure of SEP.   
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Such practical and theoretical limitations of the use of CTVB as a marker of SEP have not been reported 
in the literature to date. This supports the conclusions of the literature review within the present study 
which question the quality and scientific objectivity of studies examining CTVB as a marker of SEP 
undertaken thus far.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Introduction to CHD and rationale of the study  
 
Coronary Heart Disease (CHD) is the commonest cause of premature death in men and women in 
Scotland
1. Research has suggested that a significant proportion of incident CHD is attributable to 
modifiable risk factors such as level of physical activity, diet and smoking
2; 3. This recognition that CHD 
is a largely preventable disease has focused health policy, both in the UK and elsewhere, on prevention 
strategies
4.  
Whilst largely preventable, CHD is a complex disease; its development is influenced by a variety of 
associated factors beyond that of exposure to risk factors. The development of CHD has been shown to be 
affected by social and environmental, as well as political and economic, factors
5. 
As will be outlined later in this thesis, the evidence base for primary prevention (defined as the prevention 
of new-onset CHD) is weak. This is in contrast to that of secondary prevention (defined as the prevention 
of recurrent coronary events in patients with established CHD). However there is strong political support 
for both primary and secondary CHD prevention strategies.  There is well established evidence of a 
socioeconomic gradient in CHD
6; which presents distinct challenges for effective primary and secondary 
prevention of the disease. Moreover, beyond CHD, there is a lack of reliable evidence in relation to 
designing effective programmes to reduce health inequalities in general
7. 
Despite emerging evidence in relation to novel risk factors for CHD
8, there remains a focus on reducing 
exposure to classical cardiovascular risk factors (behavioural and physiological) in areas of 
socioeconomic disadvantage
9. A key consideration there in is the measure of socioeconomic position 
(SEP) 
10 used to define such areas or identify high risk individuals when distributing preventative 
resources. Logically individual measures of SEP may appear more sensitive than area based measures as 
not all individuals of low SEP reside in areas of socioeconomic disadvantage
11. However the use of 
individual measures of SEP is at odds with evidence which supports area contextual influences on 
health
12; 13 and the development of CHD
14.   
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1.2 Introduction to the study and organisation of the thesis 
 
This study originated from an interest in developing practical and applicable methods of identifying 
individuals at highest risk within CHD primary and secondary prevention populations. Gaps in existing 
research support a need for this. Political will exists to address inequalities in health and a drive towards 
service redesign which shifts delivery to early intervention and prevention and away from treatment and 
emergency management. Despite these widely held ideals, many barriers remain for the complete 
acceptance of these principles within the treatment and prevention of CHD; principally treatment budgets 
greatly outweigh those of prevention. This balance is unlikely to shift in the near future considering the 
inherent difficulties in generating reliable scientific evidence in relation to effectiveness of CHD primary 
prevention. A particular aspect of primary prevention with a distinct paucity of evidence concerns the 
methods of targeting and indeed engaging high risk individuals or populations; although recent studies in 
this area are beginning to emerge 
15;16. In maximising CHD primary prevention resources it is generally 
recognised that programmes should positively discriminate resource allocation in favour of individuals 
and or households of highest risk.  
Within secondary prevention there is a need to continue to monitor the quality and equity of care and 
treatment delivered within primary care to patients with established CHD. The General Medical Service 
(GMS) Quality Outcomes Framework (QOF) was introduced to universally improve the quality of care 
for CHD patients. Despite this there is evidence that inequalities in care and treatment continue to exist 
within secondary prevention. Thus it is important to characterise sub-groups of the CHD population for 
whom the introduction of the QOF has failed to ensure equitable care and treatment.  
In improving equity in both the primary and secondary prevention of CHD, the measure of SEP adopted 
is a key consideration. In both instances the more sensitive the measure of SEP (in terms of its association 
to/with cardiovascular risk in asymptomatic populations and with levels of care and treatment for 
populations with established CHD) the greater the efficiency as to how CHD preventative resources can 
be utilised. As mentioned previously it would appear that individual measures of SEP have intrinsic 
advantage
17 over area based measures. However this is problematic firstly because individual level 
markers of SEP are not routinely available for entire populations (particularly in asymptomatic 
populations). Furthermore, as stated, such an approach ignores the evidenced influence of neighbourhood 
or area of residence characteristics on health.  
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This study will investigate the use of Council Tax Valuation Banding (CTVB) as a surrogate marker of 
SEP in CHD prevention. CTVB is worthy of consideration in this context because it is sensitive to the 
household level; every household in the UK, irrespective of tenure has a council tax band. CTVB is based 
on the market value of property which reflects, to an extent, the areas socioeconomic characteristics. 
Intuitively CTVB has inherent properties which relate to SEP- property value is associated to some 
degree with individual or household income, which is one of the most accurate measures of SEP within 
cardiovascular research and beyond 
The utility of this study could be questioned given the quality of national health information collection in 
Scotland is high compared to other countries and SIMD is an established and validated national measure 
of SEP. The drive to ‘improve’ on the use of SIMD is born purely out of a desire to impact on Scotland’s 
widening inequalities in CHD.  
Using data from the Have a Heart Paisley (HaHP) Chronic Disease Register (CDR) the aim of this study 
is: 
To assess the predictive validity of CTVB in identifying elevated risk within a primary prevention 
population and sub-optimal care and treatment within a secondary prevention population.  
To address this aim, the specific objectives of the thesis are: 
1.  To examine the distribution of cardiovascular risk factors and Framingham absolute risk 
according to CTVB in an asymptomatic primary prevention population (men and women, aged 
45-60) in Paisley, Scotland in 2006 and to establish the predicative validity of CTVB with these 
variables. 
2.  To explore the rates of risk factor monitoring and secondary prevention therapies prescribing 
according to CTVB in an established CHD population (men and women with CHD of all ages in 
Paisley, Scotland) in 2009 and to establish the predicative validity of CTVB with these treatment 
and care outcome variables. 
As a precursor to these analyses the association between CTVB and SIMD, a validated national marker of 
SEP will be investigated.  
The thesis is structured in the following way: 
Chapter 1 provides an introduction, to the rationale and the aims and objectives of the study and also 
provides a guide as to the layout of the thesis.  
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Chapter 2 begins with a detailed account of the literature search strategy and literature inclusion criteria. 
The chapter then presents a literature review as a background to the thesis, including an introduction to 
the threads of research of which the thesis attempts to synthesise; CHD and atherosclerosis, global, 
European and UK perspectives of CHD and an introduction to CHD prevention strategies, this section of 
the chapter concludes with an introduction to some key considerations in addressing health inequalities. 
The chapter continues with an in-depth review of different measures of SEP in health research including 
perspectives on the contextual and compositional influences on health in general and cardiovascular 
disease specifically, this section of chapter 2 concludes with a review of the literature on CTVB as a 
proxy measure of SEP in health research to date.  
The chapter then goes on to outline perspectives on CHD primary prevention including an introduction to 
primary prevention, the historical basis of community based primary prevention, a review of evidence on 
the effectiveness of community-based primary prevention programmes, political support for primary 
prevention, an overview of the recent focus on classical versus novel risk factors in CHD and the 
distribution of classical risk factors according to SEP in asymptomatic populations. The chapter concludes 
with a brief overview of cardiovascular absolute risk measures.  
The chapter continues with an outline of perspectives on CHD secondary prevention, outlining the 
Quality and Outcomes Framework (QOF) and exception reporting and a review of evidence in equity of 
risk factor monitoring and therapies prescribing in populations with established CHD. A summary of the 
key points of the entire literature review concludes chapter 2. 
Chapter 3 describes the design and methodology of the HaHP project with a focus on aspects of the 
project relevant to this thesis. Primary care read codes and related data fields used to identify the target 
populations of interest and filter the data appropriately are described, as is the ethics approval process, 
General Practice consent and Caldicott Guardian approval of the study.  
Chapter 4 is the first of two results chapters; primary prevention population demographics are followed 
by regression analysis of the association between CTVB and SIMD in the asymptomatic primary 
prevention population. The chapter also presents box plots of the distribution of cardiovascular risk 
factors according to CTVB using this population and regression analysis to assess the significance of 
these associations. The association between CTVB and absolute cardiovascular risk is also presented; 
further regression modelling is undertaken to ascertain whether CTVB has greater strength of association 
with absolute risk in comparison to the association between SIMD and absolute risk. Analyses are 
stratified by gender.  
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Chapter 5 begins with population demographics of the secondary prevention population in Paisley in 
2009. The chapter then charts risk factor monitoring over the period 1999 to 2009; regression analysis is 
then presented to ascertain if inequalities in risk factor monitoring exist in the 2009 population only, the 
same analysis is then presented for secondary prevention prescribing. Furthermore analyses examines 
whether CTVB has greater association with risk factor monitoring and therapies prescribing in 
comparison to the associations with SIMD. 
Chapter 6 assimilates the thesis findings and discusses, in the context of the literature reviewed, the 
implications for CHD prevention and the strengths of CTVB’s predictive validity and its potential use as 
a proxy marker of SEP are considered and assessed. The strengths and weaknesses of the present study 
are described; recommendations from the study are offered. Chapter 6 concludes with a concise 
conclusion based on the present study.  
Appendices provide detail of ethics-related documentation.  
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CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction to the literature review 
 
In this chapter the approaches taken towards searching and reviewing the literature are outlined and a 
review of the literature relevant to this study is presented. The findings of the literature review are divided 
into 4 distinct topic areas:  
  Introduction to CHD and key evidence supporting the rationale for the study  
  Review of measures of socioeconomic position in health research 
  Perspectives on the primary prevention of CHD  
  Perspectives on the secondary prevention of CHD 
 
2.2 Literature review methodology 
 
2.2.1 Literature Search Strategy  
 
The literature search began in November 2008 and was repeated throughout the duration of the study- 
most recently June 2010. The literature search strategy was developed with a medical librarian at the 
University of Glasgow, by means of three meetings to ensure the literature search was as comprehensive 
and robust as possible. Electronic databases were accessed through the University’s online library 
resources. Databases used included Ovid Medline (R) 1950 to June 2010, Embase 1980 to 2010, Embase 
Classic 1947 to 1973, Health and Psychosocial Instruments 1985 to June 2010, ERIC 1965 to June 2010, 
Journals@OVID Full text, Books@OVID. Additionally searches were conducted directly within 
specialist cardiovascular journals - primarily Biomed Central, European Heart Journal, European Journal 
of Cardiovascular Prevention and Rehabilitation, Heart, British Medical Journal and Circulation. 
Furthermore seminal papers and experts within the respective fields were identified with study 
supervisors and these papers and references from these papers were explored. The search strategy was 
broken down into the four broad headings of the study detailed in the above sections and involved using 
Boolean operators and combinations of key words.  
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Key words used in the review for the Introduction to CHD and key evidence in the rationale for the study 
section included- “coronary heart disease”, “atherosclerosis”, “coronary artery disease”, “ischemic heart 
disease”, “heart disease”, “myocardial infarction”, “burden”, “global”, “UK”, “European”, “risk factors”, 
“classical”, “novel”, “absolute risk”, “high risk”, “prevention strategies”, “Scottish Health Policy”, 
“Scottish Social Policy Frameworks”, “CHD and Stroke Strategy”, “impact of CHD prevention”, 
“incidence”, “prevalence”, “primary prevention”, “secondary prevention”, “health inequalities”, “Equally 
Well”, “markers”, “proxy markers”, “novel markers”, “socioeconomic status”, “socioeconomic position”, 
“deprivation”, “social class”, “income”, “occupation”, “social stratification” and “council tax”. 
Key words used in the review of measures of socioeconomic position in health included- “health”, 
“measures”, “indices”, “markers”, “proxy markers”, “novel markers”, “socioeconomic status”, 
“socioeconomic position”, “deprivation”, “social class”, “income”, “occupation”, “education”, “area-
based”, “individual measures”, “social stratification” and “council tax”.  
Key words used in the review of CHD primary prevention included “primary prevention”, “coronary 
heart disease”, “coronary artery disease”, “ischemic heart disease”, “heart disease”, “myocardial 
infarction”, “risk factors”, “classical”, “novel”, “absolute risk”, “high risk”, “Framingham”, “ASSIGN”, 
“Q-risk”, “socioeconomic status”, “socioeconomic position”, “deprivation”, “social class”, “total 
cholesterol”, “HDL cholesterol”, “systolic blood pressure”, “diastolic blood pressure”, “body mass 
index”, “diabetes” and “smoking status”.  
Key words used in the review of CHD secondary prevention included “secondary prevention”, “coronary 
heart disease”, “coronary artery disease”, “ischemic heart disease”, “heart disease”, “myocardial 
infarction”, “risk factors”, “monitoring”, “management”, “review”, “established CHD”, “therapies”, 
“prescribing”, “ACE-inhibitor”, “anti-platelet”, “beta-blocker”, “statin”, “primary care”, “general 
practice”, “high risk”, “Quality Outcomes Framework”, “QOF”, “General Medical Services”, 
“socioeconomic status”, “socioeconomic position”, “deprivation”, “income”, “occupation”, “social 
position”, “social class” and “social stratification” 
Equivalent or comparable terms identified through thesauruses or mesh browsers were used in specific 
aspects of searches where possible. Searches were limited to English language research papers, articles 
and discussions, however no other limits were imposed. Thorough consideration was given to the key 
word search and the development of the search terms used was an iterative and progressive process, 
building on the success or otherwise of search terms tried. Despite best efforts within the scope of this 
study, it should be recognised that electronic databases use a limited range of keywords that typically  
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describe general topic areas rather than the exact area of interest of the researcher, thus, it is possible that 
some relevant research papers were overlooked despite the comprehensive nature of this literature search.  
 
 
2.2.2 Inclusion Criteria  
 
The inclusion criteria were initially deliberately broad; any English language articles that were related to 
the areas of the literature review were included; including reports, review articles and editorial 
discussions. Aspects of the search became more focussed on UK studies to enable more accurate 
synthesis of the thesis findings and not least because CTVB is a tax used in the UK only. Excluded were 
abstracts from journals of which the University was not a subscriber (thus full text was not accessible), 
although this proved an infrequent occurrence, also excluded were student theses and conference 
abstracts.  
In order to determine if articles met these criteria and were relevant to the study, the titles and abstracts of 
papers were scanned in the first instance followed by a more detailed consideration of the full text where 
doubt remained. All studies were subsequently read in entirety. As a result, in the region of 250 research 
papers were reviewed and are discussed under the four areas of the review.   
The search and inclusion criteria were undertaken to ensure that as far as possible only quality studies 
were reviewed. However given the breadth of topics synthesised in the thesis- varied study designs and 
different socio-demographic strata have been considered.  
2.3 Introduction to CHD  
 
2.3.1 CHD: a continuum of atherosclerosis 
From a biomedical perspective coronary heart disease (CHD) can be thought of as a continuum of a 
pathological process named atherosclerosis
18.  Atherosclerosis involves the coronary arteries thickening 
and hardening over time inhibiting blood flow, and the development of atherosclerotic plaques within the 
arteries, which further inhibit blood flow and risks rupturing
19. Though typically asymptomatic for 
decades
20 the resultant effects of the atherosclerotic process are chronic, slowly progressive and 
cumulative
21. The effects lead to clinical manifestations such as angina
22, and acute coronary events as a 
result of rupturing plaques; such as myocardial infarction, acute coronary syndromes and death
23.   
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Research has suggested that a significant proportion of incident CHD is attributable to modifiable 
classical risk factors such as smoking, diet, physical activity level and alcohol consumption
24. This 
recognition that CHD is a largely preventable disease has focused health policy, both in the UK and 
elsewhere, on prevention strategies
25. This perspective belies the challenges CHD presents to 
epidemiologists and public health practitioners in terms of the science of understanding the disease and 
the development of approaches to its prevention. Evidence suggests that CHD is caused by a hierarchy of 
associated factors, beyond the presence of modifiable behavioural risk factors; including social and 
environmental, as well as political and economic, factors
25. CHD appears to be a complex disease 
demanding sustained, multi-faceted approaches to reduce its global burden.  
2.3.2 CHD: Global, European and UK perspectives 
 
CHD is recognised as a leading cause of mortality and morbidity in both rich and poor countries
26.  In 
recent years CHD has been gathering unwelcome momentum in poorer developing countries 
27. The 
World Health Report, conducted in 2003
28, reported that cardiovascular diseases are now the leading 
cause of death in the majority of developing countries. Furthermore, twice as many deaths, as a result of 
cardiovascular diseases now occur in developing countries compared to developed countries, with CHD 
increasingly a key contributor to this observation.  
The decline in CHD rates in developed countries has been an emerging trend in epidemiological research 
over the past three decades
29; 30. However, these trends have been far from equitable. Across Europe, as 
CHD declining in the Western countries it was increasing in the former communist countries of Central 
and Eastern Europe; creating a profound East-West gap
31. However there is evidence of this gap 
decreasing in some Eastern European countries
32. Within European countries, including those of Western 
Europe, where CHD rates have been falling, some groups in society have not benefitted to the same 
extent as others
33;34. Most notably, considerable socio-economic variances in CHD have emerged; 
whereby those in more favoured socio-economic positions have seen steeper declines in CHD
35. As a 
result, socio-economic inequalities in CHD within developed countries
36, including Scotland
37 have 
actually risen in the past two to three decades.  
In the United Kingdom (UK), CHD mortality is higher in Scotland than anywhere else in the country
38. 
The 2007 premature death rate (individuals dying aged between 35-74 years) from CHD for men living in 
Scotland is almost double that of men living in the South West of England and is exactly double for 
women in the same comparison. The socioeconomic inequalities in CHD observed in other European  
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countries are apparent within Scotland
37. Moreover Scotland appears to have its own East-West divide 
where the post de-industrialised West-central Scotland has markedly higher rates of CHD than the East 
and North
38. The map below of the UK illustrates these two points; CHD premature death rates for men 
(left hand chart) and women (right hand chart) being the highest in local authority areas in Scotland 
compared to the majority of the rest of the UK (darker colouring), and within Scotland CHD rates are 
notably higher in West-central Scotland compared to the rest of the country (darker colouring): 
Figure 1: Age standardised death rates from CHD form men and women under 75 by local 
authority 
   
Source: British Heart Foundation Statistics Website 
2.3.3 Introduction to Strategies for preventing CHD  
 
The theory that CHD can be prevented has become increasingly popular in cardiovascular medicine in 
recent decades
39. For years there have been many prominent detractors from prevention in the field, 
however gradually prevention has come to the fore. Primary prevention can be defined as the prevention 
of new-onset CHD
40. Acceptance of the concept of primary prevention in cardiovascular medicine was 
arguably achieved through the evidenced success of secondary prevention
41- defined as the prevention of  
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recurrent coronary events in patients with established CHD
42. Secondary prevention appears to straddle 
two ideological perspectives; some cardiologists argue that secondary prevention is simply the treatment 
of coronary artery disease; others might argue that the focus is on the prevention of recurrent events
43.  
2.3.4 Estimating impact of CHD prevention strategies 
 
The prevalence (number of current cases) of CHD is influenced by a range of associated factors. To 
illustrate, a decrease in the number of new CHD cases (incidence) due to primary prevention efforts 
would reduce prevalence, however higher survival rates resulting from secondary prevention efforts, 
coupled with an aging population would actually increase prevalence
44. CHD mortality rates are also 
influenced in a similar fashion
45. Major advances in care and treatment have undoubtedly contributed to 
falling CHD mortality rates, however falling incidence rates must also be contributing to the overall 
reductions in mortality. The incidence of CHD is determined by complex interwoven factors acting over 
the life course. The contributions to reductions in mortality rates of improving these risk factors and of 
improvements in care and treatments are not completely clear. In a seminal paper Capewell and 
colleagues estimate that changes in risk factors equate to approximately a 50% reduction in mortality 
rates and improvements in care and treatments equate to a further 40%, leaving 10% un-attributable
46.  
 
2.3.5 Approaches to addressing health inequalities: CHD and beyond 
 
Beyond CHD, there is a paucity of reliable evidence relating to the most effective and cost effective 
methods or approaches when addressing socioeconomic inequalities in health. Specifically there are 
challenges regarding what approach is most successful in making sure resources are targeted at the 
highest risk populations. Area based approaches are convenient for practitioners because established 
national measures of socio-economic position tend to be area based. However identifying deprived areas 
is not the same as targeting deprived households or individuals, because not all deprived people live in 
deprived areas. It was estimated using the 1991 census that if the most deprived quintile of Scottish 
postcode sectors were targeted only 41% of unemployed individuals would be captured and only 34% of 
low income households would be captured
11.  
Furthermore the importance of this point is recognised by the Scottish Government. Within the Equally 
Well policy document:   
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  ’Area based initiatives need to be complemented by approaches which specifically target 
  disadvantaged individuals or households.’
37 
2.4 Review of measures of socioeconomic position in health 
  
This section of the review summarises literature in relation to measures of socioeconomic position (SEP) 
in health. The literature surrounding the concept of SEP is virtually immeasurable; with much debate 
continuing out with the scope of this thesis. The review describes the nature of the measures; what they 
intend to quantify, the types of data used and the strengths and weaknesses of the measures are assessed. 
The term SEP is used in the review however the terms socioeconomic status, social position, social class 
and social stratification are used in the literature summarised. It became apparent that these terms are 
however not interchangeable and refer to differing theoretical constructs and may represent differing 
interpretations; whilst this will be touched on within the review it is beyond the scope of the study to 
explore these constructs in the detail, thus to a degree these terms will be considered as having similar 
meaning.   
SEP can be broadly defined as the social and economic circumstances of an individual or group relative to 
the rest of society
47; 48.. In terms of health, SEP is associated with exposures to risk, behaviours affecting 
risk, access to resources and general susceptibility to disease or illness
49. Different measures of SEP have 
their own strengths and limitations; particularly in the context of the research field
50.  
During the review it became apparent that one of the key considerations is the differing nature of the 
theorised link between SEP and the health outcome of interest. SEP is often described as a confounding or 
explanatory factor within studies (often controlled for in analysis) but is also the core exposure or risk 
factor (and its influence on health or disease) investigated within studies. Increasingly dominant in recent 
literature is the influence or association of SEP and stage of life. It is also clear that the majority of 
measures of SEP have theoretical correlations across the stages of life, for example educational 
attainment has a clear bearing on occupation as an adult and income and specific to this study; the value 
of the house that can be purchased and thus the CTVB that the house falls under. Consistent with the aims 
of the present study, the review organises the measures of SEP in the following ways- firstly individual 
measures are considered followed by area level measures, subsequently arguments for and against 
individual and area level measures within the context of CHD and cardiovascular risk are discussed.  
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2.4.1 Education 
Education is a widely used measure of SEP particularly in epidemiological studies. The history of the use 
of education as a measure of SEP is associated with Weberian theory
51; which describes education as an 
attempt to capture the ‘knowledge related assets of a person’. Educational is influenced by parental 
characteristics and to an extent reflect the overall circumstances of a person in these early years
52.  
Education is typically measured as a categorical variable by assessing educational achievements such as 
completion of primary school, high school, college diplomas or university degree
53. Education reflects the 
circumstance of parental SEP and influences in early life but also captures the development of an 
individual into adulthood where their own socioeconomic identity begins to be realised
54. Education is a 
strong predictor of adult occupation and income
55. Thus education reflects the well evidenced association 
between early life circumstance and adult health outcomes. Indeed several studies have concluded that 
SEP across the life course influences CHD risk with childhood SEP and adult SEP both contributing to 
risk independently and cumulatively
56.  
Furthermore educational attainment has been cited as pivotal in understanding health education 
messages
57. Education may also play a role in the ability of individuals to access health services
58. 
Interestingly poor health in early years could limit educational attendance affecting adult health 
outcomes- perhaps suggesting a selective influence within health inequalities
59. 
Education is a widely used measure of SEP in health research; furthermore educational attainment is easy 
to gather and is non-intrusive to record. However educational opportunity for some sub-groups of society 
has varied greatly over the generations. Thus older individuals may be classified as less educated in some 
studies
60. Generally it proved difficult to compare and synthesise evidence using education as a measure 
of SEP due to the large variance in its recording.  
2.4.2 Housing 
 
Of particular interest to this study are measures of SEP which quantify housing circumstance and 
characteristics. Housing based indicators of SEP vary across the literature and often refer to localised 
measures of housing, particularly within rural or non-industrialised studies or countries
61. A number of 
quality studies have examined housing tenure in relation to CHD
62; 63, the former study being a 
comprehensive systematic review and the latter from a large scale Scottish cohort study. Characteristics 
within the household (access to a toilet, hot water, telephone or heating) are also used as a measure of 
SEP in some studies
64.   
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Car access is a characteristic of housing or household which is used frequently throughout UK studies as 
an indicator of SEP
65; 66.. Car access is related to the notion of socioeconomic gradients in access to health 
services
67 or retailers selling fresh fruit and vegetables
68; however it is less appropriate in rural 
populations as even the most deprived households have a car out of immediate requirement
69.  
The number of individuals living in a house commonly termed as crowding or overcrowding has been 
used as a marker of SEP
70.Links to poor health exist as a result of overcrowding
71. Cultural variances in 
numbers of family members residing in a house may not be representative of SEP.  
Housing data has strong features as a marker of SEP with clear links to income
72. Housing standard is 
often referred to as a characteristic of wealth, which can be regarded as comprising of income, financial 
and physical assets
73. Wealth has been shown to be associated with access to healthcare services, provide 
environments (residence and work) conducive to good health and allow the consumption of health 
promoting commodities (healthy diet, exercise) which has an important effect on health
74. The limitations 
of the housing measures of SEP reviewed are the inherent dependence on the context of the study; in 
terms of geography and study population of interest. Thus the literature was difficult to synthesise and 
generalise there on.  
2.4.3 Income 
 
From the literature reviewed it is apparent that income is generally regarded as the most accurate measure 
of SEP available
75. Income as an indicator of SEP directly measures material resources and 
circumstance
76. There is a correlation between increasing income and better health outcomes
77; 78. The 
association between income and health is accepted across the literature yet the causal mechanism is rarely 
explored, representing a gap in evidence. Few studies reviewed directly consider income expenditure on 
health promoting commodities.  
Income is usually measured in categories
79. Household income is less frequently reported and in some 
studies this is considered by family size or dependants 
80- this theoretically provides a more accurate 
reflection of the resources available to the household
81.  
Personal income may be a sensitive subject and people may be reticent in providing it
82. No studies 
reviewed acknowledged the possibility of the over reporting of income. Income is strongly associated 
with educational attainment and occupation
83; 84. Arguably disposable income would be the best measure 
of SEP, which over and above costs of living would reflect available resource to consume commodities  
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relating to health; this could be further enhanced by considering family size
85. Less often income is 
considered over the life course
86; this is important as income tends to increase with age, thus SEP will 
continually rise over the life course making the interpretation of SEP somewhat variable
87.   
2.4.4 Occupation 
 
Occupation based measures of SEP are widely used in the literature 
88-90. Similar to education, occupation 
has historical links to Weber’s theory that SEP should reflect a person’s standing in society. Thus 
occupation reflects educational attainment, intellectual capacity and the underlying social class
91. Similar 
to income, stage of life is a consideration in using occupation as a marker of SEP
92, some studies refer to 
parental occupation as a measure of early years SEP relating to adult health outcomes
93. Thus occupation 
reflects the transferability of material circumstances from one generation to the next. Occupation of the 
head of the household is often used to reflect the SEP of the family or household
94.  
Occupation is usually referred to in categories in the literature (manual, professional etc) and was the 
measure of SEP used in the Whitehall study
95; 96 where the occupational grades of civil servants were 
categorised and the distribution of cardiovascular risk factors and outcomes were analysed accordingly 
revealing stark occupational inequalities in the disease.  
Similar to income and housing, occupation can be considered to have an indirect bearing on health in 
terms of the degree to which health promoting commodities can be purchased
97. Occupation type also has 
interesting characteristics relating to health; lower income manual jobs may have greater exposure to 
environmental hazards and higher physical demands
98. Lower income jobs are also categorised as 
repetitive, unsupportive and having little autonomy resulting in poorer overall health outcomes
99.  
Occupation has been well recorded for a long time, notably in British death records and in census data 
collection
100. The most appropriate method of recording the occupation of unemployed, retired, carers or 
those in illegal jobs is problematic; health inequalities may be under-represented in studies which do not 
included such individuals
101. Furthermore inaccuracies are inevitable when attempting to quantify 
occupation across a limited range of categories. Moreover, temporal analysis using occupation as a 
measure of SEP is problematic due to the changing nature of the modern workforce
102. 
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2.4.5 Area-level measures 
 
Area level measures of SEP are aggregated from individual data and small area characteristics, usually 
from census and government administration data sources. They characterise areas on a scale from most to 
least deprived. Area-based measures represent only a proxy measure of SEP for the individuals living in 
those areas. In the UK there has been a relative proliferation of composite area based measures in recent 
years, such as the Townsend deprivation index
103, the Carstairs deprivation index
104, the Jarman or 
underprivileged area (UPA) score
105 and the Scottish Index of Multiple Deprivation (SIMD)
106. The 
SIMD is used in subsequent analysis in this study. The SIMD comprises of 37 indicators of SEP in seven 
domains: current income, employment, health, education, skills and training, geographic access to 
services (including public transport travel times), housing tenure and crime levels. SIMD is based on 
aggregated data within defined geographical parameters called data zones which on average contain 
approximately 800 individuals. Data zones are then refined into deciles or quintiles; a continuum of 
socioeconomic deprivation
107.  
The key strengths of area based measures such as SIMD is that they are official and available for the 
entire nation and easily linked to study populations
108. Area measures of SEP are complete, clean datasets 
and are unobtrusive and cheap to gather and use
109. Furthermore area based measures are less prone to 
misclassification than individual measures
110. 
Area based measures  the socioeconomic conditions of an area to some extent; thus whilst area based 
measures are derived from aggregated individual level data and other sources the relationship to health is 
primarily described as the area’s influence on health
111.  
2.4.6 Discourse in the literature; contextual and compositional influences on health; area versus 
individual measures of SEP 
 
There is an ongoing debate within the literature regarding the merits of area-based versus individual 
measures of SEP and which are most appropriate to use in health research in general and for particular 
disease and study types
112-118. The focus of the debate in relation to CHD has been to describe the wider 
influences on CHD mortality and morbidity which are not fully explained by classical risk factor analysis 
at the individual level
119;120. Thus, the scope of studies has expanded to explore how the socioeconomic 
environment of an area affects the health behaviours and outcomes of those living there
121; 122. Geographic 
variance in cardiovascular risk and health behaviours is often described within the literature as the  
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compositional (i.e. how many people residing in the area smoke, lead a sedentary existence etc) or the 
contextual influences (i.e. transport, access to fresh fruit and vegetables, quality of housing, access to safe 
environments to exercise etc) on
123.  
Uncertainty regarding the balance between compositional and contextual influences and the interplay with 
SEP on the development of CHD limits preventative strategies in important ways
124. If there are primarily 
compositional explanations for the socioeconomic inequalities in CHD then prevention strategies should 
focus on the individual; thus utilising individual measures of SEP where possible
125; 126. On the other hand 
a contextual explanation would mean action on the wider living and working conditions in an area; 
targeting geographical areas or neighbourhoods; thus the measures of SEP used in resource allocation 
should be area-level indicators
127;128.  
From the evidence reviewed it appears that both contextual and compositional factors influence 
behaviours, exposure to risk factors and cardiovascular outcomes. It is interesting to note within the 
literature reviewed that many studies report associations between either contextual and compositional 
influences or area-based and individual measures of SEP to the detriment of the association with the 
other. In other words it appears that the theoretical construct which underpins many papers in this field is 
that contextual or compositional influences on health cannot co-exist.  
A recent study which defies this construct found independent effects of both individual SEP and 
residential area deprivation on classical behavioural risk factors - smoking, exercise and diet. The study 
concluded that although community SEP and individual SEP may affect each other, they also operate 
through separate pathways to affect health behaviours
129 and that this is what is important. An important 
influence explored by Mitchell
130; 131 has been proximity and access to natural green space, straddling both 
contextual and compositional ideologies of health behaviour influence.   
2.4.7 CTVB as a proxy household-level measure of SEP  
 
The Council Tax was introduced by the British Government in 1992 and is based on the market value of 
British homes as at 1
st April 1991 (for Wales the valuation date is 1
st April 2003). The valuation then 
places the home into one of eight bands- A-H with band A being the lowest and band H the highest. 
Houses built or modified since 1991 are valued in the present day and then devalued to 1991 levels for 
banding. Council tax banding data is accessible information, at a household level, under the freedom of 
information act, either online or through local valuation boards. The range of property values according to 
council tax for Scotland and England are shown in the below two tables:  
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Table 1: Council Tax Valuation Bandings for Scotland 
 Council Tax valuation bands  Ranges of property values in Scotland
 A   up to £27,000 
 B   over £27,000 and up to £35,000 
 C   over £35,000 and up to £45,000 
 D   over £45,000 and up to £58,000 
 E   over £58,000 and up to £80,000 
 F   over £80,000 and up to £106,000 
 G   over £106,000 and up to £212,000 
 H   over £212,000 
 
 
There is one Council Tax bill for every property in the UK. Usually the person living in the property has 
to pay the Council Tax Bill. Spouses and partners who live together are jointly responsible for paying the 
Council Tax bill. The below list represents a hierarchy of responsibility for paying Council Tax, the bill 
payer being the individual who:  
• lives in the property and owns it 
• lives in the property and has a lease (this includes 'assured tenants' under the Housing Act 1988) 
• lives in the property and is a 'statutory' or 'secure' tenant 
• lives in the property and is not a tenant but has permission to live there 
• lives in the property (for example a squatter) 
• has a lease of six months or more on the property, but does not live there 
• owns the property but does not live there 
The use of CTVB as a surrogate marker of SEP in health research has been limited to date and has been 
investigated in small studies, primarily within primary care. Beale has led the use of CTVB as a marker of 
SEP. In a 2001 study, Beale et al began exploration of CTVB as a marker of SEP by establishing its  
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association with the ‘Jarman Index’
133. The Jarman index or Under-privileged area 8 (UPA8) score is an 
established marker of SEP developed in the 1980s and is based on 8 socioeconomic factors available from 
UK census returns. Beale et al conclude that CTVB and the Jarman index are highly correlated but that 
CTVB is a stronger predictor of GP workload. Unlike the Jarman index, Beale argues that CTVB is 
simple, objective, and free of the problems of Census data. Furthermore CTVB, being household-based, 
can be aggregated at will.   
In 2002, Beale et al undertook a study to determine the association between the CTVB of residence and 
mortality risk using the death registers of a UK general practice
134. The study findings from analysis of 
856 deaths were that consistent and significant differences in death rates between CTVBs exist. Above 
average mortality was identified in bands A and B residents; below average for other band residents. The 
study concludes that CTVB of final residence appears to be a surrogate marker of mortality risk and could 
be a worthwhile indicator of health needs resource at a household level.  
In 2005 Beale et al investigated the costs of daily clinical activities within a general practice by gender, 
age and SEP as measured by CTVB
135. The results of the study were strong- CTVB was as strong a 
predictor of patient care cost as patient gender and age. The study concludes that NHS planning and 
resource allocation could be simplified and enhanced by using CTVB as a marker of SEP.  
In 2006 Beale et al used data from the ALSPAC sample (Avon Longitudinal Study of Parents and 
children) to investigate the association between CTVB and breast-feeding rates
136. The study concludes 
that CTVB predicts breast-feeding rates and that CTVB could be used for accurate resource allocation 
within community paediatric services.  
 
Whilst Beale et al’s work has been innovative; the study populations used (with the exception of the 
ALSPAC breast feeding study) have exclusively been the general practice from which the lead author 
works. These studies have small sample sizes and give little insight into the socio-demographics of the 
population. The accuracy of primary care records can be questioned as their primary purpose is 
administrative rather than for official recording. Furthermore Beale et al make no reference to housing 
tenure as having a possible confounding effect on the theorised link between income, material 
circumstance and CTVB. The paper makes no reference to the data linkage of CTVB. Thus the accuracy 
of CTVB as a measure of SEP is arguably not properly critiqued, theoretically or practically in these 
studies. Indeed Beale’s discussion in each of the published papers appears to lack scientific objectivity. 
The conclusions are so strikingly in unequivocal support of CTVB as a marker of SEP above all other 
measures that it detracts from the credibility of the research.   
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In a larger 2006 study
137, Fone et al looked to assess CTVB as a measure of SEP by comparing the 
strength of the associations between selected health and lifestyle outcomes. The study found that there 
were significant trends in odds ratios across the CTVB categories for all outcomes, most marked for 
smoking and mental and physical health status. The associations with CTVB were higher than that of the 
established measures of SEP considered in the study. The study concludes that CTVB deserves further 
consideration as a proxy for SEP in epidemiological studies in Great Britain. Unlike Beale, Fone et al 
acknowledge that there were anomalies in data linkage and that CTVB does not distinguish between 
owner-occupied and rented accommodation.  
 
Findlay et al were the first to relate CTVB to cardiovascular outcomes
138. This 2006 study used data from 
the HaHP CDR to investigate the association of CHD incidence had a closer association with CTVB than 
with SIMD The correlation coefficient between SIMD score and CHD incidence for all ages was 0.71 and 
for CTVB was 0.89. The correlation coefficient for those aged 45–60 was 0.90 and 0.98 respectively. The 
below figure chart the latter analyses; the chart on the left shows the distribution of CHD incidence by 
SIMD and the chart on the right shows the distribution of CHD incidence by CTVB: 
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Figure 2: Findlay et al, Distribution of CHD incidence according to SIMD and CTVB in 45-60 year 
old men and women in Paisley 2005 
 
 
 
The study concludes that CTVB should be explored as a simple measure to individualise the correction 
that needs to be applied to standard risk calculators to account for the influence of deprivation on CHD 
risk. This paper has been pivotal to the present study; it is arguably the highest quality study of CTVB as 
a marker of SEP as it uses accurate hospital discharge data required for national morbidity and mortality 
records.  
 
Theoretically CTVB incorporates many of the characteristics of the measures of SEP covered thus far. 
CTVB is a measure of housing value; this has theorised links to material circumstance relating to 
education, occupation and income. The value of the house purchased must reflect to an extent these 
characteristics of SEP. CTVB being sensitive to the household level is close to an individual measure of 
SEP. However housing value is influenced also by area characteristics and the socio-demographic 
compositions of areas. For example, identical tenement housing stock varies dramatically in value within 
the present study; as the areas vary from most to least deprived according to SIMD. Crucially CTVB is 
available for entire populations and requires no collection. 
 
2.5 Perspectives on Primary Prevention of CHD  
 
2.5.1 Introduction to the primary prevention of CHD 
The Scottish National CHD and Stroke strategies of the past decade state that effective primary 
prevention is a key priority in reducing the burden of CHD
37. Despite this, resource allocated for care and 
treatment far outweigh that of prevention
139; 140. Evidence as to the effectiveness of primary prevention is  
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mixed
141; 142. The difficulty in generating quality evidence from primary prevention programmes is 
however recognised
143; 144.  
In 1995 the WHO European Working Group on Health Promotion Evaluation
145 state that using 
randomised control trials (RCTs) to evaluate such programmes is inappropriate. Thus CHD primary 
prevention research often falls short of scientific approval. Most CHD primary prevention programmes 
are community-based programmes
146-148; in contrast to the financial might of the pharmaceutical industry 
arguably these programmes may appear colloquial and underfunded
149.  
2.5.2 The historical basis of community based CHD Primary Prevention 
Since the 1970s there have been countless CHD primary prevention interventions and programmes. The 
nature of primary prevention programmes delivered has varied, involving risk screening drug therapies, 
educational and media programmes as well as community development activities. Wider focus has also 
been on health related legislation and policy - such as food retailing and cigarette advertising
150.  
Some of the earlier primary prevention interventions such as the North Karelia Project
151 and the Stanford 
Three City Projects
152 have been influential to similar large-scale community based trials- the Stanford 
Five City Project
153, the Minnesota Heart Health Project
154 and the Pawtucket Heart Health Project
155 
2.5.3 Assessing the impact of CHD primary prevention 
In 1999 Lundvall et al
156 published a systematic review of  CHD primary prevention programs. The 
authors included only high quality studies involving a control group.  Eight studies were included in this 
review: 
Table 2: CHD primary prevention interventions considered in Lundvall et al, systematic review 
Community based CHD prevention 
programme 
Nation of study and 
Year  
Authors 
North Karelia   Finland 1972–1977  
Pushka et al
157.  
Vartiainen et al
158.  
The Stanford Three City Projects  
US – California 
1972-1975  
Farquhar et al
159.  
The Stanford Five City Project  
US – California 
1980-1986  
Farqhuhar et al
160.  
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Community based CHD prevention 
programme 
Nation of study and 
Year  
Authors 
Minnesota Heart Health Program  
US -Minnesota 1981-
1988  
Luepker et al
161. 
Pawtuckett Heart Health Program  
US -New England 
1981-1994  
Carleton et al
162. 
German Cardiovascular Prevention 
Programme  
Germany 1984-1991  Hoffmeister et al
163 
Swiss National Research Programme  Switserland 1985-  Gutzwiller, et al
164 
Kilkenny Project  Ireland 1985-1992  Shelley et al
165  
 
The Lundvall review concluded that outcomes were insignificant and that the differences seen between 
intervention and control areas were negligible in terms of reductions in classical risk factors or CHD 
incidence.  They summarised that: 
  ‘There is no conclusive scientific evidence that would support starting new large scale community 
  intervention programmes – such as those assessed here – aimed at preventing cardiovascular 
  disease. The eight large community intervention projects reviewed in this report have not 
  demonstrated any significant effects on risk factor levels or disease incidence beyond those 
  observed in populations at large’  
There have been some studies of primary prevention interventions where classical risk factors have shown 
significant reductions
166; 167, however, it remains unclear if these reductions are large enough to impact on 
CHD morbidity or mortality. 
 In 1997, Ebrahim and Davey-Smith conducted a comprehensive systematic review and meta-analysis
168 
which aimed to assess the effect of multiple risk factor primary prevention interventions in reducing total 
mortality, CHD mortality. All the trials and interventions included in the analysis were randomised 
designs. The paper considered interventions from 1966 to 1995..   
Davey-Smith concluded that these interventions had no effect on mortality given that the pooled effect for 
both CHD and total mortality was 0.97:  
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  ‘Multiple risk factor interventions comprising counselling, education, and drug treatments were 
  ineffective in achieving reductions in total mortality or mortality from cardiovascular disease 
  when used in general or workforce populations of middle aged adults. The pooled effects of 
  intervention were insignificant, but a potentially useful benefit of treatment (about a 10% 
  reduction in mortality from coronary heart disease) may have been missed’.  
Furthermore, the risk factor changes that occurred were modest; the authors suggested that they may even 
have been overestimated due to issues of measurement, analysis and study design: 
  ‘The changes in risk factors associated with interventions were modest but are probably 
  optimistic estimates as changes could be measured only in those remaining in the trials. 
  Habituation to blood pressure measurement, regression to the mean and self reports of smoking 
  will also tend to exaggerate the changes observed’. 
 
2.5.4 Political support for CHD primary prevention 
 
In the face of convincing evidence to the contrary policy makers continue to support CHD primary 
prevention. The role of scientific evidence in policy making is a complex and nuanced paradigm
169.  
2.5.5 Focus of primary prevention: classical versus novel cardiovascular risk factors 
 
In recent years epidemiological research into CHD risk-factors has reached a crossroads. One route 
suggests there is already convincing evidence to take effective preventative action against CHD in 
relation to classical behavioural and physiological risk factors 
170. The other route argues that classical 
risk factors only explain a proportion of the socio-economic gradient in CHD
171; 172. The latter path has 
thus seen a drive to identify new risk factors to further the understanding of CHD aetiology; lipoprotein, 
C-reactive protein, fibrinogen, homocysteine, microalbuminuria, inflammation, anti-oxidant intake, fish 
intake, air pollution, personality types, oral hygiene and gene-environment interactions to name but a 
few
173.  
The literature suggests that research into emerging risk factors should be continuous
174; however focus on 
classical risk factors should remain the key priority in CHD prevention. The American Heart 
Association’s (AHA) position is clear; classifying major risk factors as those that research has shown 
significantly increase the risk of CHD, these include risk factors that cannot be changed (increasing age,  
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male gender and heredity) and those which can be modified or controlled through lifestyle change or 
taking medicine (tobacco smoking, high blood cholesterol, high blood pressure, physical inactivity, 
obesity and diabetes). The AHA recognises novel risk factors but states that they have not yet been 
precisely determined
175.  
Individuals of lower socio-economic position continue to have significantly greater exposure to classical 
risk factors
176. Research suggests that a proportion of increased risk  in areas of socioeconomic 
deprivation is due to coping behaviours
177; 178.  
Whilst the exact interaction of classical risk factor exposure, SEP and heredity susceptibility are not 
completely understood in the development of CHD, a progressive step in recent literature has been to at 
least view SEP as an independent risk factor. A Scottish study thus incorporated SEP as a risk factor 
when calculating absolute cardiovascular risk in screening
179. This inclusion increased the predictive 
power of the risk calculator. Whether SEP is considered as an independent risk factor
180 or termed as a 
contributing risk factor
175 is inconsequential; to maximise the use of CHD preventative resources SEP is a 
core consideration. 
The focus on classical risk factors and SEP is further underlined when exposure is considered over the 
life-course
181; 182. It is argued that the explanatory power of classical risk factors can be massively 
underplayed
183; 184 by a single measurement in mid-life. This viewpoint casts doubt over the need to 
‘explain’ why measurements of classical risk factors explain only a proportion of the socioeconomic 
gradient in CHD
185. Thus a key priority for CHD preventative programmes continues to be the focus on 
reducing exposure to classical risk factors targeting individuals or areas of low SEP
186.   
2.5.6 Cardiovascular risk factors in CHD asymptomatic populations and SEP 
 
SEP, measured by occupation, educational level and income is related to mortality and morbidity from 
CHD
187. Evidence suggests that the most marked improvements in cardiovascular health have occurred 
among higher SEP populations, whilst progress among lower SEP populations has been slower
188. Overall 
evidence points to lower SEP populations having greater exposure to risk factors; such as smoking, 
unhealthy diets, sedentary lifestyles and have worsened psychological profiles
189.  
The literature review will now focus on the distribution of selected classical risk factors; gender and age, 
diabetes, cholesterol, blood pressure, body mass index and smoking status according to measures of SEP.   
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2.5.6.1 Gender and age 
 
There are differences in CHD risk between the sexes, CHD is between 2 to 5 times more likely to develop 
in men than women
190. In both men and women the risk of CHD increases significantly with age but the 
rate of increase is sharper for women. Differences in classical risk factors explain a substantial proportion 
of the gender differences in CHD risk
191. The sharp increase in CHD risk seen in women in later life is 
associated with the decrease in oestrogen production post menopause and the effect this hormonal change 
has on lipid metabolism
192.  
2.5.6.2 Diabetes 
 
The presence of non-insulin dependent (Type II) diabetes is associated with increased risk of CHD and 
excessive CHD mortality and morbidity. The INTERHEART study estimates this elevated risk as being 
increased 3 fold
193. Furthermore diabetes rates increase as SEP decreases
194;195, particularly amongst 
women and ethnic groups
196-198, however this relationship is not reported across all the literature
199;
200.  
2.5.6.3 Cholesterol 
 
CHD risk is related to blood cholesterol levels
201. The World Health Organization report 2002 estimates 
that 8% of all disease burden in developed countries can be attributed to raised cholesterol levels
28. 
Furthermore the report estimates that 60% of incident CHD and 40% of stroke is due to raised cholesterol.  
The relationship between SEP and total cholesterol level is less clear. Many studies report an inverse 
relationship between SEP and serum cholesterol
202; 203, but not all
204.  
High density lipoprotein (HDL) cholesterol is commonly referred to as ‘good’ cholesterol because it 
removes cholesterol from the blood via the liver
205. Low levels of HDL cholesterol are associated with 
increased CHD risk. Evidence exists of socioeconomic variance within lipids- with lower SEP individuals 
having higher levels of total cholesterol and lower levels of HDL cholesterol
206.  
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2.5.6.4 Blood Pressure 
 
Raised blood pressure (BP) levels or hypertension is a CHD risk factor. An inverse relationship between 
BP and SEP is reported throughout the literature
207-209. Irrespective of the measure of SEP adopted the 
literature consistently reports that lower SEP individuals have higher rates of elevated BP (both systolic 
and diastolic)
210.  
Lower rates of education and awareness of hypertensive risk have been identified in deprived 
communities
211. The combination of genetic susceptibility and job strain (physically demanding/low 
autonomy/decision making authority roles) has been shown to contribute towards raised blood pressure
212. 
Foetal mal-nutrition has also been shown to play a role in increasing the susceptibility for hypertension in 
adulthood
213.  
2.5.6.5 Smoking 
 
Smoking significantly increases the risk of CHD
214. It has been estimated that one fifth of all 
cardiovascular related deaths are attributed to smoking
28. Passive, second-hand smoke is also a 
cardiovascular risk factor
215.  
Smoking is consistently related to SEP. The key theme emerging is that individuals of lower SEP are 
more likely to smoke
216;217; this association is consistent across all ages and gender
218 and is irrespective 
of the measure of SEP
219 . Overall smoking rates have been decreasing but have been decreasing at a 
significantly slower rate in areas of lower SEP
11. 
2.5.6.6 Body Mass Index 
 
Obesity is a CHD risk factor. Obesity is an independent CHD risk factor and is also a major contributor 
towards raised blood pressure, increased blood cholesterol, impaired glucose tolerance and diabetes
220. 
7% of all disease burden in developed countries is due to raised body mass index (BMI) and one third of 
CHD and stroke and almost 60% of hypertensive disease is as a result of being overweight (BMI from 25-
30 kg/m
2) and obese (BMI ≥ 30 kg/m
2)
28. Increased cardiovascular risk is posed when excess weight is 
concentrated around the lower abdominal area. Waist to hip ratio is used to measure this phenomenon and 
literature refers to it as central or abdominal obesity
221; 222.   
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The literature reviewed concerning the relationship of SEP to obesity concludes that women of lower SEP 
are more likely to be obese than the rest of the socioeconomic strata
223, but that in men the association is 
far less clear
224;225.  
2.5.6.7 Identifying high risk- screening strategies and measures of absolute cardiovascular risk 
 
National, structural, health improvement policy aims to lessen the population distribution of risk through 
appropriate legislation- smoking bans, reduced salt/fat in food etc
226. Such legislation is an important 
aspect of primary prevention. The majority of evidence reviewed suggests that primary prevention should 
be targeted at those with the highest risk. Some argue however that this may actually widen 
inequalities
227. Others advocate a duel approach; both legislative and highest risk targeting
228-230.Engaging 
lower SEP communities in primary prevention demands nuanced approaches
16  
CHD risk factors affect each other cumulatively tending to cluster in high risk populations. This has seen 
the development of multivariable risk prediction algorithms which allow rapid assessment of absolute 
cardiovascular risk. Absolute measures of risk have been advocated to guide treatment of risk factors. The 
Framingham CHD risk assessment tool uses age, sex, family history of CHD, systolic blood pressure, 
total and HDL cholesterol, diabetes status, and smoking status to generate the chance (expressed as a %) 
of developing CHD in the next 10 years
231. Individuals with a Framingham score ≥ 20% are considered to 
be high risk.  
The Framingham score has been criticised because it does not encompass SEP as a risk factor. In 2005 
Tunstall-Pedoe and co-workers
232 added SEP (as measured by SIMD) into the Framingham equation to 
derive the ASSIGN score. The ASSIGN score increased the predictive power of cardiovascular outcomes 
ahead of  Framingham. Soon after Hippsley-Cox et al
233 derived QRISK, which in addition to classical 
risk factors used in Framingham also includes BMI, family history of cardiovascular disease, social 
deprivation (Townsend score) and the use of antihypertensive treatment. The study concludes that QRISK 
was better calibrated to the UK population than either the Framingham model or ASSIGN.  
Jackson et al
234, strike a sobering note as to the accuracy of risk prediction tools, stating that all tools yield 
modest results and that QRISK is no different classifying 10% of men in the UK as high risk however 
only 30% of subsequent cardiovascular events in men occurred in this high risk group. Framingham 
classifies twice as many men in the UK as high risk, although this larger group does not include twice as 
many of the men who had a cardiovascular event during follow-up (it included only 50%). Thus the  
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margin for improvement is small; indeed Framingham predicts a larger quantity of high risk individuals if 
not as accurately. The below figure illustrates this point; representing the predictive power of QRISK and 
Framingham: 
Figure 3: Jackson et al, Accuracy of QRISK and Framingham absolute risk measures 
 
2.6 CHD mortality and SEP 
 
Critical to primary prevention strategies (and secondary prevention) has been the association between 
CHD mortality and SEP. CHD mortality is higher in the most deprived; this has been reported in the 
literature for over 50 years
235. A recent Scottish study investigating CHD mortality using SIMD as the 
measure of SEP concluded that premature death from CHD remains a major contributor to social 
inequalities. Furthermore, the plateau in the decline in mortality for CHD among younger adults of lowest 
SEP is worrying
236. Similar findings have been observed in other Scottish studies
237; 238. The studies 
reviewed have not controlled for the effects of risk-factors on mortality. 
2.7 CHD Incidence and SEP 
 
One large study (2.6 million people) examined the entire Swedish population (aged 40-64) and found an 
association between CHD incidence and income; although only sex and age were adjusted for in the  
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analysis
239. However in another study which did adjust for classical risk factors, income was associated 
with increased incidence in both men and women
240.  
 
2.8 Perspectives on Secondary prevention of CHD 
 
2.8.1 Introduction to Secondary Prevention of CHD in Primary Care 
 
In comparison to primary prevention of CHD, secondary prevention of the disease has established 
guidelines and stronger evidence.  The at risk population are clearly identified.  The care and treatment of 
individuals with CHD is well established and the impacts of secondary prevention are significant
241; 242. 
That said there remains evidence of inequalities in the delivery of secondary prevention
243. The focus of 
secondary prevention strategies in the UK literature has been on exposure to risk factors, both behaviour 
risk (stopping smoking, adopting a healthy, balanced diet and cardiac-rehabilitation) and physiological 
risk (cholesterol, blood pressure, body mass index). The appropriate treatment through secondary 
prevention medications (anti-platelet therapy, statins, ACE inhibitors and beta-blockers, if there are no 
specific clinical contraindications) is also pivotal
244; 245.  The importance of secondary prevention drugs 
cannot be underplayed; they are estimated to account for 10% of the reduction in CHD mortality rates in 
the UK and are thought to be an inexpensive and effective prevention method
246.  
Most patients with CHD are cared for in primary care
247. In recent years there has been much research 
into secondary prevention treatment and practice among patients with CHD in primary care
248. In 1999 
the UK CHD National Service Framework recognised that 100% uptake of secondary prevention 
therapies in primary care is unrealistic and set national targets of 80%
249. Yet evidence suggests that even 
these targets remained challenging
250; 251. In 2004 the General Medical Services (GMS) introduced the 
Quality Outcomes Framework (QOF)
252, in which scores attained are now directly linked to general 
practitioner remuneration. The QOF contract has set national standards for quality CHD care based on a 
variety of indicators including regular classical risk factor monitoring, advice and referral on smoking and 
prescribing appropriate secondary prevention therapies. Figure 4 below details the targets set in the QOF 
for the secondary prevention of CHD, this figure is extracted from a 2007 study
253.  
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Figure 4: GMS QOF indicators and targets in secondary prevention of CHD 
 
2.8.2 Exception reporting within the QOF contract 
 
General practitioners are remunerated for providing quality CHD care. Payment is equally weighted 
across the socio-demographic strata. Arguably this was designed to eradicate the potential for inequalities 
in care across CHD populations. The QOF contract does not positively discriminate in favour of or seek 
to identify individuals who are receiving sub-optimal care or disease management. The QOF contract 
contains ‘exception reporting’ which allows general practitioners to receive care payment when they have 
not seen patients face-to-face. The general practitioners select patients for exclusion against set criteria. 
Exception reporting was included in the QOF in order that practices would not be penalised for the 
characteristics of the patient socio-demographic they serve. Reasons why a patient might be exception 
reported include:  
  patients who have been recorded as refusing to attend review;  
  patients who have been invited on at least three occasions during the preceding twelve months; 
  patients for whom it is not appropriate to review the chronic disease parameters due to particular 
circumstances, e.g. terminal illness or extreme frailty;  
  patients newly diagnosed within the practice, or who have recently registered with the practice;  
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   patients who should have measurements made within three months and delivery of clinical 
standards within nine months, e.g. blood pressure or cholesterol measurements within target 
levels;  
  patients who are on maximum tolerated doses of medication whose levels remain sub-optimal; 
   patients for whom prescribing a medication is not clinically appropriate, e.g. those who have an 
allergy, another contraindication or have experienced an adverse reaction,  
  where a patient has not tolerated medication,  
  where a patient does not agree to investigation or treatment (informed dissent), and this has been 
recorded in their medical records,  
  where the patient has a supervening condition, which makes treatment of their condition 
inappropriate, e.g. cholesterol reduction where the patient has liver disease,  
  where an investigative or secondary care service is unavailable. 
2.8.3 Equity of CHD secondary prevention care and treatment in primary care 
 
Primary care studies have shown that more affluent communities experience a higher standard of care. 
Failing to match quality and inclusive care to the needs of communities may lead to the inverse care law 
described by Tudor Hart where communities with the highest prevalence of CHD and other chronic 
diseases
254; 255 are the least likely to access healthcare services. A 2006 study
256 concludes that exception 
reporting within the QOF does not incentivise the additional work required to engage and care for 
individuals of lower SEP in the management of CHD. Furthermore Downing et al’s
253 (2007) findings 
suggest that target-based remuneration of primary care dampens sensitivity to inequalities and will do 
little to improve the health of disadvantaged groups. 
 
2.8.4 Equity of risk factor monitoring in primary care under the QOF 
 
The quality of primary care studies, which are predominantly based on administrative databases, can be 
questioned, especially in contrast to studies analysing national health outcomes records. However the 
limitations of the data sources are acknowledged within the field.  
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The literature points to the introduction of the QOF in 2004 as having a substantial increase in the 
proportion of individuals with CHD having regular risk factor reviews
257; however findings in relation to 
the socioeconomic, gender and age equity in QOF risk factor review delivery are mixed. In 1998 (pre-
QOF) Campbell et al conducted a study within 89 general practices. One of the main findings of the study 
was that nearly two thirds of the study population had at least two aspects of their health behaviour that 
would benefit from increased levels of monitoring, however there was little socioeconomic variance in 
these findings
258.  
A 2006 study reported practice-level CHD prevalence was associated with deprivation but that there was 
no socioeconomic difference in risk factor monitoring
259. In a 2008 study
260 using data from all general 
practices in England, no significant socioeconomic inequality risk factor monitoring was found, however 
neither of these studies considered exception reporting. A study comparing rates of risk factor monitoring 
between QOF practices in Northern Ireland and non-incentivised primary care in Ireland concluded that 
cholesterol and blood pressure monitoring was higher in the QOF practices
261. 
A 2007 primary care study of 55,522,778 patients in England and Scotland concluded that there were 
clear socioeconomic differences in risk factor monitoring (particularly where further investigation was 
required) was higher in GP surgeries in more affluent areas
254. Furthermore, McLean et al was one of the 
first studies to identify that exception reporting played a part in masking socioeconomic inequalities in 
care and treatment within 17 of 33 QOF indicators; including smoking status, blood pressure and 
cholesterol recording. This seminal study and others
262 conclude that whilst ‘payment quality’ in isolation 
suggests no socioeconomic variance in risk factor monitoring. However, the removal of exception 
reporting, leaving actual ‘delivered quality’ demonstrates that inequalities in monitoring of these key 
cardiovascular risk factors persists
256.  
 
2.8.5 Equity of secondary prevention therapies in primary care under the QOF 
 
The literature reviewed demonstrates that secondary prevention therapies prescribing has increased over 
the past 10 years and as a result of the introduction of the QOF
263;264. However analysis of the impact of 
the QOF introduction in 2004 on prescribing demonstrates an already increasing prescription rate of 
secondary prevention therapies before 2004. It could be argued that this increase in prescribing paralleled 
the pre- QOF improvements in clinical care  and was influenced by national guidelines or local managed 
clinical networks
265.   
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In a 2006 seminal paper, Capewell et al
266 highlight that in 2000 barely half of individuals with CHD in 
England and Wales were receiving optimum secondary prevention and that if 80% had being receiving 
appropriate therapies then 20,000 deaths may have been prevented or postponed over this period. The 
paper generally supports the introduction of the QOF.  
A 2006 study demonstrated that there were no socioeconomic variances in secondary prevention 
prescribing
267. Studies prior to the implementation of the QOF have shown significant socioeconomic 
inequalities in rates of statin prescribing
268; 269. However in a 2007, post-QOF study, Ashworth et al
255 
demonstrated using a cross-sectional survey of all general practices in England, that socioeconomic 
inequalities in statin prescribing were not apparent; however older individuals were less likely to be 
prescribed statin therapies. Similar age inequalities in statin prescribing and other secondary prevention 
therapies has been an ever emerging theme in the literature in recent years and is supported by other 
studies
270;271. Indeed age and gender differences in secondary prevention therapies emerged in a 2003 
study where older men and women were less likely to be prescribed optimum therapy combinations and 
women generally were less likely to receive optimal prescribing compared to men
272. 
A randomised control trial within primary care demonstrates the overall improvements that can still be 
made within therapies prescribing for patients with CHD. This  study highlights that even after the 
introduction of QOF sub-optimal prescribing is still apparent in primary care
273. A 2006 study using data 
extractions from 201 UK general practices reported that Prescribing of anti-platelet and statin drugs is at a 
high level. However, the study noted that there is still scope for improvement in secondary prevention by 
increasing use of beta-blockers, ACE-inhibitors and other blood pressure lowering drugs in patients who 
can tolerate them. This and other studies conclude that there are strong age inequalities in secondary 
prevention prescribing in general and especially amongst individuals with less severe symptoms
274;275. 
2.9 Literature Review Summary 
 
The scope and diversity of the literature reviewed in this study is ambitious. This concluding section of 
the literature review will attempt to briefly synthesise and summarise the key themes and discourse in the 
literature. Additionally this section will illustrate where the present study fits with the literature reviewed 
and how the interpretation of this study’s findings will add value.  
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2.9.1 Introduction to CHD 
 
CHD is a complex, multi-faceted disease and its development is influenced by many factors over the life-
course. CHD can be thought of as a continuum of the pathological process atherosclerosis. CHD is 
recognised as a leading cause of mortality and morbidity in both rich and poor countries. Overall rates of 
CHD have been declining; however the decline has been far from equitable. The decline in rates of CHD 
has been far less pronounced in individuals or groups of lower SEP. This presents real challenges to 
effective prevention of CHD; which has strong political support within the UK and other countries. When 
approaching CHD prevention SEP and thus the measure of SEP is a key consideration.  
 
2.9.2 Measures of Socioeconomic Position 
 
The concept of SEP is fundamental to the thrust of preventative medicine as there are profound 
socioeconomic gradients across many diseases, care and treatments. The literature search identifies many 
measures of SEP; all of which have strengths and weaknesses- both theoretically and in practical terms. 
The quality of national health information collection in Scotland is high and SIMD is an established and 
validated national measure of SEP. The drive to ‘improve’ on SIMD in terms of CTVB’s potential 
increase in predictive validity is born purely out of a desire to impact on Scotland’s widening inequalities 
in CHD.  
CTVB is worthy of consideration as a surrogate marker of SEP as it has appealing characteristics in 
comparison to other markers of SEP. The current literature assessing CTVB as a marker of SEP is limited 
and the quality of the studies is questionable. Only one study has used CTVB in cardiovascular research. 
The use of CTVB as a marker of SEP in the current study is completely novel. Current discourse in the 
literature surrounds the influences on health and health behaviours; contextual or compositional. This 
debate theoretically merges somewhat with evidence exploring the merits of area-based or individual 
measures of SEP. The quality of health information in Scotland is high 
2.9.3 Primary Prevention of CHD 
 
Evidence and policy review suggests it is generally accepted within CHD primary prevention that the 
highest risk individuals should receive the greatest amount of resource. Given the socioeconomic gradient 
in CHD mortality, morbidity and exposure to most classical risk factors; individuals or groups of lowest  
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SEP represent elevated risk. The evidence base for effective primary prevention of CHD is however 
weak. Particularly there is little evidence relating to identifying and engaging high risk individuals from 
the wider population. Despite the weaknesses in primary prevention evidence, political support appears 
unwavering. The use of CTVB as a marker of SEP to identify and target high risk individuals from the 
wider population is appealing both theoretically and in terms of practical ease-of-use in programme 
delivery. The present study will assess if CTVB has a stronger association with cardiovascular risk factors 
and absolute risk than SIMD in an asymptomatic population; this, the literature review suggests, is 
completely novel research. Due to the characteristics of SIMD and CTVB, the findings of this analysis 
can be related to the debate within the literature concerning the contextual/compositional influence on 
health. However within the limits of this study this is a theorisation only. Aside from the interest in 
CTVB as a proxy marker of SEP, the literature reviewed suggests there remains value in the exploration 
of socioeconomic inequalities in classical cardiovascular risk factors and absolute risk in this 
asymptomatic population. Debate within the literature concerns the limited power of classical risk factors 
in explaining the socioeconomic gradient in CHD; it is beyond the scope of this study to add significantly 
to this debate. The accuracy of absolute risk measures has been criticised in the literature. 
2.9.4  Secondary Prevention of CHD 
 
The evidence base for secondary prevention of CHD is strong, particularly in contrast to that of primary 
prevention. The QOF was introduced to improve the quality of CHD patients’ care and disease 
management within primary care. The QOF financially incentivises the monitoring of risk factors and 
appropriate therapies prescribing within CHD populations. The evidence reviewed suggests there are 
mixed reports as to the equity of QOF implementation in relation to risk factor monitoring and therapies 
prescribing in established CHD populations. One such focus in this area has been on the notion of 
“exception reporting”; essentially where a GP receives remuneration when they have not actually seen the 
patient. Exception reporting is recorded against pre-defined criteria, one of which concerns patients who 
have not responded to invites for risk and medication review. Limited evidence suggests that this area of 
exception reporting creates socioeconomic inequalities in those actually accessing review; the QOF does 
not recognise the extra effort required to engage individuals of low SEP. The present study records 
individuals who have not responded to invites for risk and medication review (but QOF payment has been 
made) as having not had risk factor and medication review. With the review data thus filtered, 
socioeconomic inequality in risk factor monitoring and therapies prescribing rates are assessed using 
CTVB and SIMD. Evidence reviewed suggests this is novel research. Aside from the exploration of 
CTVB as a marker of SEP this analyses is important, characterising individuals who are underserved by  
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current QOF arrangements may have strong implications for the future delivery of CHD secondary 
prevention within primary care.  
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CHAPTER 3: METHODS  
3.1 Introduction  
 
This chapter gives an overview of Phase 2 of the Have a Heart Paisley (HaHP) project which ran from 
2006 to 2008. It provides a detailed explanation of how data used in this thesis was collected in the HaHP 
project and the subsequent redevelopment of the HaHP CDR in 2009. Also included are details as to the 
strict ethical approval process adhered to by the study, with relevant documentation included in the 
appendices.  
3.2 Have a Heart Paisley 
 
3.2.1 Phase One 
 
HaHP began as a partnership between NHS Argyll & Clyde, Renfrewshire Council, voluntary and 
community organizations and the people of Paisley in October 2000. HaHP aimed to provide a uniting 
focus for action across a broad front to prevent CHD, promote good health and reduce health inequalities 
in Paisley, Scotland's largest town. Phase One of HaHP took a population wide approach. The aim of this 
approach was to raise awareness of CHD and its risk factors as well as design interventions targeting 
those at high risk and to change the risk profile of the whole population. Independent evaluation of Phase 
1 was not positive. The evaluation of HaHP and other community health initiatives suggests that targeting 
the whole population is over-ambitious and the timescales on which it expected to deliver were 
unrealistic.  
3.2.2 Phase Two 
 
In 2003, The Scottish Government signaled commitment to a second phase of HaHP. In Phase Two, 
HaHP moved from a population approach to a method that focused support for those most at risk of 
developing heart disease.  The vision for Phase 2 was to deliver, through the combined efforts of its 
community, voluntary, local authority and NHS partners; primary and secondary preventive interventions 
that would improve heart health by tackling classical risk factors, with a particular focus on those in 
deprived communities.   
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3.2.3 The Have a Heart Paisley Chronic Disease Register  
 
A development in Phase 2 of HaHP that is fundamental to this study is the Chronic Disease Register 
(CDR). The CDR was set up primarily to identify the primary and secondary prevention populations 
within Phase 2 of the project, but laterally broadened its scope to be a comprehensive hub of CHD related 
data for the town of Paisley, with links to lab results, coronary care units, Scottish Morbidity Records and 
General Practice (GP) systems. Figure 5 below is an extract from a 2005 published editorial describing 
the CDR
276. The CDR performed regular electronic extractions of patient data from Paisley GPs. Using 
primary care read codes the CDR was able to identify individuals aged 45 to 60 who were free from 
cardiovascular disease and diabetes (primary prevention) and those with CHD of all ages (secondary 
prevention population).  
This study uses risk factor data from the original HaHP primary prevention cohort as identified using the 
CDR in 2006, and is thus linked to SIMD and CTVB data. The present study does not however use the 
original secondary prevention population identified in 2006 using the CDR. Instead an updated secondary 
prevention population has been identified using 2009 data extracted from the CDR. All CDR 
development, administration and data linkage carried out there in is undertaken by the NHS Greater 
Glasgow & Clyde Health Information and Technology Department at Westward House, Paisley. 
Figure 5: Clark et al, CDR data sources interface 
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3.3 Read codes used to define primary and secondary prevention populations 
 
Read codes are used to record clinical summary information, their main benefit is that they allow some 
standardisation of the way information is recorded in primary care. Read codes were developed within a 
framework of disease areas or chapters. Read codes are 5 characters long and if there is no character after 
the initial disease area character then the remaining characters are represented by dots. Read codes are 
organised as a hierarchy; the higher up the hierarchy the less specific the code is, for example:  
G…. Circulatory system diseases 
G3… Ischaemic Heart Disease 
G30.. Acute Myocardial Infarction 
G30y, Other Acute Myocardial Infarction 
G30y2 Acute Septal Infarction 
Exploratory analysis of read code usage in the CDR shows variation between general practices in Paisley. 
In terms of clinical accuracy the more characters that are present- the more accurately defined the 
patient’s condition is, however this is time consuming for practice staff to ensure this accuracy. 
Furthermore in terms of audit and disease registers it is more efficient to group disease types using fewer 
characters within the read codes.  
All methods adopted in designing the GP data extractions within the CDR to meet the needs of the study 
were heavily influenced by the Health Information and Technology Development Department of NHS 
GG&C and reviewed by the cardiologist and consultant in public health medicine attached to the study.  
To identify the primary prevention population, read codes were used in reverse- that is an “is not” 
operator was used in the query within the CDR to filter patients without cardiovascular (CHD and 
cerebrovascular diseases) and diabetes (Type 1 and 2) read codes (Read codes- G3***, G6***, C10E, 
C10F). Patient age was derived from date of birth recorded under “PAT_DOB” field and thus filtered 
down to individuals aged 45 to 60 years old as of 1
st of February 2006.  
To identify the secondary prevention population queries were set up within the CDR that enabled the 
CHD heading to be captured as well as all sub categories of disease there in- G3*** (* denotes 
‘wildcard’-query returning all read codes beginning with G3). This method has been validated in similar  
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studies
256. The data was captured at 31
st December 2009 (and at this date for each preceding year of the 
recording period, 1999-2009, for risk factor recording and therapies prescribing trend analysis only); risk 
factor monitoring and therapies prescribing are considered for this population in the preceding 12 months 
(a minimum of 1 recording of the risk factor or review and prescription of therapies was recorded as a 1, 
where none had occurred over the 12 month period a 0 was recorded). 
To establish the rate of risk factor monitoring the following fields within the GP administration system 
were required to be populated: BP_DAT, (date of blood pressure measure) CHOL_DAT, (date of 
cholesterol measure) SMOK_DAT, (date of smoking status recording) and BMI_DAT (date of BMI 
recording). For these data the CDR query was also designed to ensure a valid value was associated with 
the read code of each risk factor and the date of recording. An important point to note in the analysis of 
risk factor monitoring is that where an exception code (recorded against any of the four risk factors), 
which described a patient who had been invited to attend for secondary prevention review on 3 occasions 
but had not attended; this was recorded within the CDR query as no risk factor monitoring had occurred 
within the recording year. This decision was taken in line with other studies which aim to highlight the 
potential for socio-economic inequalities under the existing exception reporting within the QOF 
contract
256. As advised by the cardiologist attached to the study, this is the only exception code that was 
removed as the remaining codes stray into clinical judgement which was deemed unsuitable to comment 
on within the scope of this study
277-279. To review QOF implementation datasets and business rules 
including read codes and exception reporting codes in full, links to electronic resources are provided
280-285 
in the references section of the thesis.    
To establish the rate of secondary prevention prescribing the following fields within the GP 
administration system were considered for individuals with an existing CHD diagnoses read code - 
BB_COD, BB_DAT (beta-blocker prescribed and date of prescription) ACE_COD, ACE_DAT (ACE-
inhibitor prescribed and date of prescription), CLO_COD, CLO_DAT (Clopidogrel; anti-platelet 
prescribed and date of prescription). Querying statin prescribing was more difficult as it is not actually a 
QOF target in its own right; other than through QOF cholesterol level targets. Statin prescribing was 
identified using British National Formulary (BNF) drug therapies codes
286 held within GP records. Indeed 
the Health Information and Technology Development Department of NHS GG&C recommended cross 
referencing the read code query for anti-platelet, ACE-inhibitor and beta-blocker therapies by using BNF 
drug therapies codes to identify secondary prevention therapies prescribing. Variance between the data 
returned using the two methods for these three therapies was negligible. Exception reporting within 
therapies prescribing was filtered in the exact same manner as risk factor monitoring, described above.   
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3.4 Linkage of socio-economic indices within the CDR 
 
 
CTVB data was originally linked, using postcode and address, within the CDR in 2006. A more recent 
download of Paisley council tax data was requested from the Renfrewshire Joint Valuation Board (RJVB) 
in February 2009. The RJVB have an obligation to provide council tax data under the freedom of 
information act however requesting data for the entire town represented a non standard request incurring a 
£100 administration charge. This charge was paid from the study’s budget.  
SIMD data zone data from 2006 was held within the Health Information and Technology Development 
Department of NHS GG&C. SIMD data was linked to CDR using patient postcode. At the time of 
conducting the analysis (over 2009 and early 2010) the 2006 SIMD data was the most recent SIMD data 
available. However at the time of writing the new SIMD data gathered in 2009 is now in the public 
domain. 
3.5 CDR Ethics, patient consent and data-linkage  
 
A detailed ethics application including a description of the study with particular attention to the use of 
patient data and patient consent for this data usage was submitted to the South Greater Glasgow and 
Clyde (SGG&C) Local Research Ethics Committee (LREC) via the Integrated Research Application 
System (IRAS) on October 24
th 2008. The application supported that the CDR should be updated and data 
linkage redeveloped in order to ensure accuracy of study findings. The application also explicitly stated 
that all data extracted from the CDR to be used in this study will be completely anonymous and non-
identifiable. The SGG&C LREC then considered the application during their November 2008 meeting 
and ethics approval was granted on the letter marked 28
th November 2008 (Appendix A).  
The ethics application submitted recognised that it would be an inefficient use of time and resources to 
attempt to gather informed consent from the Paisley populations of interest. The application described 
how awareness raising of the CDR and the option for Paisley citizens to opt out (opt out form is included 
as Appendix D) of the use of their records in the CDR was posted to all individuals in Paisley with CHD 
(secondary prevention population) and those deemed to be at risk (the primary prevention population- 
aged between 45- 60 years old and currently free from cardiovascular disease and diabetes) in 2006. The 
ethics application recognised that only 2 opt-out forms were received from a target population in the 
region of 15,000 individuals. Thus it was deemed that reasonable attempt to gather informed patient  
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consent at a population level had been undertaken
287. The SGG&C ethics committee were in agreement 
with this.  
In order for data linkages within the CDR to be updated explicit approval was sought from the NHS 
Greater Glasgow & Clyde (GG&C) Caldicott Guardian. The Caldicott Guardian was thus written to in 
October 2008 and approval was granted via a hand signed letter in December 2008 (Appendix B). NHS 
GG&C Research and Development (R&D) sponsorship and approval was also sought and received in 
December 2008; all supporting documents outlined were forwarded on to R&D at this time. 
Additionally consent was sought from Paisley General Practices in order that the CDR could extract their 
patient records for analysis. The letter sent to Paisley GPs is in Appendix C. Of the 13 practices 
contacted, 1 practice refused to allow the study access to their patients’ records. The reason for refusal 
was not directly related to concerns over the study or patient confidentiality, rather it was misgivings the 
GP and practice manager had, based on a prior negative experience of the data extraction method. The 
practice in question used the EMIS GP electronic records system whereas the rest of the Paisley GPs used 
the GPASS system. The GP in question stated that a prior extract had created problems in the EMIS 
system and that the method of extraction was not suitable for the EMIS system. This was regrettable as 
this meant the study had incomplete data as regards the entire Paisley population. That said the GP’s 
views were respected and data from the practice was not included in any of the analysis.  
3.6 Gathering physiological risk data in the primary and secondary prevention population 
 
As described, the primary prevention population was identified using GP read codes to exclude patients 
with a history of cardiovascular disease and diabetes mellitus. Some 11,270 patients met these criteria. 
Patients thus selected were invited to participate in the study. They were informed about the study 
through local media and mass mailings. Of the 11,270 eligible individuals, 1,894 individuals attended 
screening at a convenient community location and were asked to give informed consent. The location was 
designed in order to overcome barriers to recruitment faced by those of lower SEP. A questionnaire 
recorded family history of CVD and some behavioural risk factors including smoking status. In addition, 
patients underwent a physical examination by a qualified nurse. The examination consisted of blood 
pressure, cholesterol, weight and height. Blood pressure was measured in a sitting position with a 
validated sphygmomanometer. Two measurements were taken separated by at least 10 minutes; the mean 
of these readings was used in the analysis. Cholesterol was measured with a portable ‘Cholistech’ 
(Cholistech Corp, Hayward, California) machine; blood samples were taken using a finger pin prick. 
Height and weight were measured by standard procedures. As recommended in British national guidelines  
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patients with a Framingham score ≥ 20% were considered high risk
180. These patients’ results were 
communicated to their GP and a further blood sample was taken and sent to the laboratory to measure 
fasting glucose, haemoglobin and lipid profiles as part of a more thorough investigation. 
Using the Framingham equation
20, each patient’s 10 year risk (%) of developing a CVD event was 
calculated. The formula for Framingham risk includes the following independent variables: gender 
(male/female), age (in years), systolic blood pressure (mm Hg), serum total cholesterol, and high density 
lipoprotein (HDL) cholesterol, diabetes mellitus (yes/no), body mass index (kg/m2) and current smoking 
status (yes/no).  
In the secondary prevention population all physiological measures were taken by a qualified practice 
nurse or the GP themselves.   
3.7 Statistical techniques  
 
All data used in analysis was anonymous and non-identifiable in line with ethics approval. All analyses of 
the primary prevention population were stratified by sex. All analyses were explored initially through 
box-plots. Linear regression was then used throughout whereby Council Tax Band A was the control 
from which differences in the distribution of the risk factor or Framingham score were measured against 
in the other Council Tax Bands (i.e. Bands B to G). Regression analyses were undertaken to:  
1) Test  the  association  between SIMD and CTVB.  
2)  Test the associations between cardiovascular risk factors and CTVB (except for association 
between current smoking status and CTVB for which logistic regression was used).  
3)  Test the association between Framingham risk score and CTVB. Likelihood ratio tests were used 
to test the significance of the associations at a significance level of 0.05.  
Analyses in the secondary prevention section of the results were not stratified by sex. Linear regression 
was used throughout whereby Band A was the control from which differences in risk factor monitoring 
and therapies prescribing were measured against in the other Council Tax Bands (i.e. Bands B to G) or 
SIMD quintiles (where quintile 1 was the control to measure against quintiles 2 to 5). The effects of age 
and sex are adjusted for within the regression analyses to ensure that findings are not skewed by 
circumstantial variation between council tax bands or SIMD quintiles. Likelihood ratio tests were used to  
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test the significance of the associations at a significance level of 0.05. Regression analyses were 
undertaken to:  
1)  Test the significance of differences between levels of risk factor monitoring (cholesterol, blood 
pressure, smoking status and body mass index) between council tax bands.  
2)  Test the significance of differences between levels of secondary prevention therapies (ACE-
inhibitor, anti-platelet, beta-blocker and statin) prescribing between council tax bands.  
3)  To establish if CTVB has an independent contribution over and above SIMD in the above two 
analyses. 
Before adjustment for age was carried out, the linearity of effect with respect to the particular outcome 
was tested by adding an age squared term into the model. If significant this term was retained in the 
adjustment to account for the curvi-linear association between age and the outcome in question.  
AIC (The Akaike information criterion) are also calculated in multiple regression models. This additional 
test is included as it is used to compare models. The better fitted model is the one having the smaller AIC 
value. Differences between models are used to illustrate the degree of preference
288.  
The c-statistic is also calculated for analyses involving binary outcomes within the secondary prevention 
cohort. The c-statistic equals the area under a receiver operating characteristic (ROC) curve and is 
commonly used to measure the performance of models predicting dichotomous outcomes
289. 
All analyses were undertaken using Stata (version 10) statistical analysis software.  
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CHAPTER 4: RESULTS, THE PREDICTIVE VALIDITY OF CTVB AS A MEASURE OF SEP 
IN THE PRIMARY PREVENTION OF CHD  
4.1 Primary Prevention Population Demographics and Risk factor summary 
 
Table 3: Baseline characteristics and summary of cardiovascular risk factors in asymptomatic men 
and women aged 45-60 years of age, Paisley, West of Scotland, 2006 
 Males Females
Total   815 (44.1) 1,079 (55.9)
Age (years) 52.4  (4.8) 52.9 (4.6)
Current Smoker†  213 (19.7%)  186 (22.8%) 
Family History of CVD†  439 (53.9%)  669 (62.0%) 
Systolic BP (mm Hg)  141.9 (16.6)  132.1 (17.4) 
Diastolic BP (mm Hg)  88.3  (11.0) 84.4 (11.2)
Serum total cholesterol (mmol/l) 5.4 (0.9) 5.4 (0.9)
Serum HDL cholesterol (mmol/l) 1.2  (0.4) 1.5 (0.4)
Body Mass Index (kg/m
2) 27.6  (4.2)  27.3  (5.1) 
Waist (cms)  99.1 (12.0)  89.0 (12.8) 
Obesity rate (BMI=30 kg/m
2) 209  (25.6%)  272  (25.2%) 
10 year CVD absolute risk (%)  13.5 (7.0)  6.6 (4.5) 
Values are mean (SD) or number (%) 
†Based on patients’ self reports 
BP, blood pressure; CVD, cardiovascular disease; HDL, high density lipoprotein 
   
Cases utilised: 1,894 
The above table lists the variables of interest in this part of the study. The total sample size is 1,894 and 
100% of risk factor data fields are complete i.e. there are no missing cases. All data were linked to CTVB 
successfully. It is understood that having 100% of data is unusual within health-related research data, 
however it should be recognised that this data was gathered by a dedicated, specialist evaluation team 
within a national health demonstration project and is not a secondary data source extract.  
Almost two thirds of the study population were women (55.9%).The mean age was: 52.4 years in men 
and 52.9 in women.  Around a fifth were current smokers; 19.7% of men compared to 22.8% of women. 
More than a half of all men (53.9%) and almost two thirds of the women (62%) reported a family history 
of CVD.   
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4.2 Distribution of SIMD Score according to CTVB 
 
This analysis plots the distribution of SIMD score according to CTVB. This is undertaken to establish the 
association between SIMD and CTVB and assess whether CTVB can be thought of as a marker of SEP. 
The below box plot charts the distribution of SIMD scores (y-axis) according to CTVB (x-axis): 
Figure 6: box plot, distribution of SIMD score according to CTVB by gender 
 
Cases utilised: 1,894 
From the box plot it is clear there is an association between SIMD and CTVB. This association will now 
be formally established using linear regression analysis. As can be seen in the below regression output 
table there was a highly significant association (p<0.0001 and R
2=0.40) between CTVB and SIMD Score. 
As the CTVB increased the mean SIMD and hence average level of socioeconomic deprivation decreased 
so that the mean SIMD in the lowest value housing was 42.02 for males and 41.2 for females compared to 
9.30 for males and 10.32 for females in the highest value housing:
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Table 4: Regression of SIMD according to CTVB by gender in Primary Prevention population 
CTVB Male  Female 
Mean 
SIMD 
95% CI  p-Value Mean 
SIMD 
95% CI  p-Value 
A  42.02  (39.99 to 44.04)  -  41.21  (38.53 to 44.01)  - 
B  -5.09  (-8.74 to -1.44)  <0.001  -2.58  (-5.96 to 0.79)  0.13 
C  -14.44  (-18.83 to -10.06)  <0.001  -8.25  (-12.28 to -4.22)  <0.001 
D  -26.41  (-30.43 to -22.39)  <0.001  -25.09  (-28.79 to -21.39)  <0.001 
E  -31.54  (-35.38 to -27.70)  <0.001  -29.69  (33.27 to -26.12)  <0.001 
F  -32.51  (-36.62 to -28.41)  <0.001  -29.54  (-33.46 to -25.62)  <0.001 
G  -35.51  (-41.08 to -29.94)  <0.001  -30.94  (-35.69 to -26.18)  <0.001 
   
Cases utilised: 1,894 
4.3 Distribution of classical risk factors according to CTVB and gender 
The distribution of each classical CHD risk factor according to CTVB and gender will now be plotted 
using a box-plot.  
4.3.1 Distribution of systolic blood pressure according to CTVB by gender 
Figure 7 below shows the distribution of systolic blood pressure by CTVB for females and males in the 
primary prevention population:  
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Figure 7: box plot, distribution of systolic blood pressure according to CTVB in asymptomatic 
population, by gender 
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Cases utilised: 1,894 
The distribution of systolic blood pressure appears relatively evenly distributed across the CTVB banding 
for both men and women. 
 
4.3.2 Distribution of diastolic blood pressure according to CTVB by gender  
 
Figure 8 below shows the distribution of diastolic blood pressure according to CTVB for females and 
males in the primary prevention population:  
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Figure 8: box plot, distribution of diastolic blood pressure according to CTVB in asymptomatic 
population, by gender 
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Cases utilised: 1,894 
Similarly the distribution of diastolic blood pressure appears evenly distributed across the CTVB; there is 
a slight gradient in males where diastolic blood pressure in band G seems higher than band A. 
 
4.3.3 Distribution of body mass index according to CTVB by gender  
 
Figure 9 below shows the distribution of body mass index (weight in kilograms divided by height in 
metres squared) according to CTVB for females and males in the primary prevention population:  
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Figure 9: box plot, distribution of body mass index according to CTVB in asymptomatic 
population, by gender 
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Cases utilised: 1,894 
The distribution of BMI across the CTVB is interesting. It would appear from the box plot that females in 
the lower CTVB (bands A, B and C) have higher BMI than those in higher bands (noticeable E and F). 
Whilst for males the reverse seems true, BMI appears to increase as CTVB increases.  
4.3.4 Distribution of total cholesterol according to CTVB by gender  
 
Figure 10 below shows the distribution of total cholesterol according to CTVB for females and males in 
the primary prevention population:  
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Figure 10: box plot, distribution of total cholesterol according to CTVB in asymptomatic 
population, by gender 
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Cases utilised: 1,894 
The distribution of total cholesterol appears to slightly increase as CTVB increases, particularly in 
females. In general the distribution of total cholesterol in each CTVB is quite wide.  
4.3.5 Distribution of HDL cholesterol according to CTVB by gender  
 
Figure 11 below shows the distribution of high-density lipoprotein (HDL) cholesterol according to CTVB 
for females and males in the primary prevention population:  
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Figure 11: box plot, Distribution of HDL cholesterol according to CTVB, by gender 
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Cases utilised: 1,894 
The distribution of HDL cholesterol across CTVB is quite striking in both females and males. It appears 
that as CTVB increases so too does HDL cholesterol. Females have a broader range of HDL cholesterol 
values within CTVBs compared to males and have markedly higher values in general.  
4.3.6 Distribution of current smokers according to CTVB by gender  
 
Figure 12 below shows the distribution of current smokers according to CTVB for females and males in 
the primary prevention population:  
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Figure 12: Distribution of current smokers according to CTVB, by gender 
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Cases utilised: 1,894 
The distribution of current smokers by CTVB is striking with a near perfect socioeconomic gradient in 
both males and females; where individuals of lower CTVB had much higher rates of smoking. 
4.4 Multiple Linear Regression: Distribution of classical cardiovascular risk factors according to 
CTVB 
 
This regression analysis is undertaken to establish the association between cardiovascular risk factors and 
CTVB in the primary prevention population. Table 5 however begins by detailing the distribution of risk 
factors across the council tax bands: 
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Table 5: Distribution of classical risk factors in asymptomatic primary prevention population according to CTVB 
   CTVB  A  B  C  D  E  F  G 
   Value 
§ 
Up to 
£27,000 
£27,000 to 
£35,000 
£35,000 to 
£45,000 
£45,000 to 
£58,000 
£58,000 to 
£80,000 
£80,000 to 
£106,000 
£106,000 to 
£212,000 
Cardiovascular 
risk factors 
Gender                                           
Systolic 
Blood 
Pressure  
M 139.88 1.68 143.99 2.05 142.28 2.46 141.19  2.25 142.5 2.15 139.73 2.3 142.13 3.12
(mm Hg)  F  133.59 1.49 133.05 1.84 133.16 2.19 133.1  2.01 130.5 1.94 131.68 2.13 131.8 2.59
Diastolic  
Blood 
Pressure 
M 86.88 1.1 89.58 1.35 87.38 1.62 87.81  1.49 87.84 1.42 88.38 1.52 89.88 2.06
(mm Hg)  F  84.11 0.96 85.03 1.18 85.69 1.41 85.04  1.29 83.1 1.25 82.7 1.37 85.29 1.67
Body Mass 
Index 
M 26.4 0.43 27.74 0.52 27.82 0.62 27.85  0.57 27.33 0.55 27.79 0.58 28.69 0.79
(kg/m
2) F 28.09 0.44 27.92 0.54 28.51 0.64 26.82  0.59 26.45 0.57 26.2 0.62 27.01 0.76
Serum total  
Cholesterol  
M 5.19 0.09 5.32 0.11 5.35 0.14 5.44  0.13 5.35 0.12 5.45 0.13 5.54 0.17
(mmol/l) F  5.37 0.08 5.44 0.1 5.44 0.12 5.36  0.11 5.5 0.1 5.41 0.11 5.71 0.14
Serum HDL  
Cholesterol  
M 1.22 0.04 1.17 0.05 1.22 0.05 1.2  0.05 1.26 0.05 1.29 0.05 1.34 0.07
(mmol/l) F  1.42 0.03 1.39 0.04 1.45 0.05 1.5  0.04 1.54 0.04 1.61 0.05 1.56 0.06
Current   M  46.94 0.5 32.02 0.48 31.4 0.47 10.57  0.31 13.07 0.34 11.61 0.31 5 0.22
Smokers (%) †
  
F 40.14 0.49 29.66 0.5 26.27 0.46 14.37  0.44 26.72 0.35 7.63 0.27 0 0
Cases utilised: 1,894 
§ based on 1991 housing value 
† based on self reporting 
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Table 6: Output of regression, distribution of classical risk factors by CTVB in the asymptomatic 
primary prevention population 
  
From regression, 
un-adjusted 
From 
regression, 
adjusted for age 
and age-
squared*  
From 
regression, 
adjusted for age, 
age-squared* 
and SIMD 
Cardiovascular 
risk factors 
Gender P-
value 
AIC P-
value 
AIC P-
value 
AIC 
Systolic 
Blood 
Pressure  
M 0.32  6902.1 0.4 6894.7 0.33 6896 
(mm Hg)  F  0.61  9237 0.48 9217.6 0.52 9219.6 
Diastolic  
Blood 
Pressure 
M 0.39  6224.4 0.48 6223.3 0.49 6225.3 
(mm Hg)  F  0.17  8288.3 0.16 8290.4 0.32 8291.1 
Body Mass 
Index 
M 0.056  4668.2 0.053 4672 0.12 4672.5 
(kg/m
2) F  <0.001  6583.4 <0.001 6587 0.13 6584 
Serum total  
Cholesterol  
M 0.3  2192.04 0.26 2194.6 0.82 2192.8 
(mmol/l) F  0.17  2888.4 0.4 2837 0.28 2837.6 
Serum HDL  
Cholesterol  
M 0.14  671.4 0.13 670.3 0.34 672.1 
(mmol/l) F <0.001  1017.9 <0.001 1015.4 0.05 1009.2 
Current   M  <0.001  809 <0.001 806.8 <0.001 800.1 
Smokers (%) †  F  <0.001  1020 <0.001 996.1 0.03 944.3 
*age-squared term proved to have significant association with all therapies 
prescribing and was thus retained in adjusted models to account for the curvi-linear 
association between age and the therapy prescribing outcome in question 
Cases utilised: 1,894 
Table 6 above details the output of risk factor regression analysis. The table contains p-values as well as 
AIC values. The values are presented under the three models were the regression distribution of the risk 
factor variables are undertaken in unadjusted, adjusted for age and age-squared and adjusted for age, age-
squared and SIMD models. BMI (females, marginal significance in males), HDL Cholesterol (females) 
and rates of current smokers (males and females) all proved to have significant association with CTVB in 
the unadjusted model.  
These associations remained relatively unchanged when adjusting for age and age-squared in the second 
model. However based on the p-values, the addition of SIMD into the third model tends to weaken the  
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independent contribution of CTVB with BMI (males and females) HDL cholesterol (females) and current 
smokers (females). 
The smaller AIC of 6584 with a model that includes age, sex, CTVB, SIMD compared with AIC of 6587 
with a model that includes age, sex, CTVB indicates that SIMD is improving model fit; the difference in 
models being 3. Hardin and Hilbe
288 state that a difference in AIC values of greater than 2 and less than 8 
between models is a ‘positive’ degree of preference. Similar positive preferences in differences between 
AIC values for the same model comparison are evidenced in HDL Cholesterol in females (6.2 difference 
in AIC value) and rates of current smokers in males (6.7 difference in AIC value). However the difference 
in AIC values for the same model comparison in female current smoker rates is 51.8, indicating a very 
strong preference for the model with SIMD included. 
4.5 Regression modelling: Distribution of Framingham absolute cardiovascular risk according to 
CTVB 
 
The following analysis concludes this results chapter and is undertaken to assess the strength of 
association between Framingham risk and CTVB. Firstly a box-plot is used to explore the association and 
finally regression modelling is used to quantify the association.   
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Figure 13: box plot, distribution of absolute cardiovascular risk (measured by Framingham Risk 
Score) according to CTVB in asymptomatic primary prevention population, by gender 
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Cases utilised: 1,894 
There appears to be a socioeconomic gradient in Framingham risk score in both men and women; 
Framingham score is higher in both men and women in the lower value housing (Bands A, B and C) 
compared to the Framingham risk scores in the higher value housing (Bands E, F and G), however Band 
G (the highest value properties) seems to go against this gradient somewhat as it would appear that in 
both men and women the Framingham risk tends to increase going from Band F to Band G.   
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Table 7: Regression analysis, association between Framingham risk and CTVB in asymptomatic primary 
prevention population, by gender 
Model 1. From regression of CTVB and Framingham Risk, adjusted for age and age squared* 
   Males Females 
CTVB 
Reg 
Coeff  95% CI  p-value 
Reg. 
Coeff  95% CI  p-value 
         <0.001        <0.001 
B  -0.39  (-1.93 to 1.15)  0.617  0.31  (-0.56 to 1.17)  0.486 
C  -1.42  (-3.27 to 0.42)  0.131  -0.34  (-1.37 to 0.69)  0.52 
D  -2.46  (-4.15 to -0.77)  0.004  -1.51  (-2.45 to -0.56)  0.002 
E  -2.55  (-4.16 to -0.93)  0.002  -1.94  (-2.85 to -1.03)  <0.001 
F  -3.39  (-5.12 to -1.66)  <0.001  -2.4  (-3.41 to -1.40)  <0.001 
G  -2.95  (-5.30 to -0.61)  0.014  -1.96  (-3.18 to -0.74)  0.002 
Model 1  R
2=0.17, AIC=5340.0  R
2=0.13, AIC=6198.7 
Model 2. From regression of CTVB and Framingham Risk, adjusted for age, age  squared*and 
SIMD 
   Males Females 
CTVB 
Reg 
Coeff  95% CI  p-value  Reg Coeff  95% CI  p-value 
         0.01        0.04 
B  -0.38  (-1.93 to 1.17)  0.629  0.41  (-0.45 to  1.26)  0.349 
C  -1.39  (-3.28 to 0.51)  0.151  0  (-1.03 to 1.03)  0.998 
D  -2.4  (-4.26 to -0.54)  0.012  -0.51  (-1.52 to 0.50)  0.326 
E  -2.47  (-4.33 to -0.61)  0.009  -0.77  (-1.78 to 0.25)  0.138 
F  -3.31  (-5.28 to -1.34)  0.001  -1.23  (-2.46 to 0.55)  0.027 
G  -2.87  (-5.44 to -0.30)  0.028  -0.76  (-2.05 to 0.53)  0.247 
Model 2   R
2=0.17, AIC=5342.0  R
2=0.15, AIC=6129.0 
Cases utilised: 1,894 * 
age-squared term proved to have significant association with all therapies prescribing and was thus retained in adjusted models to account for the 
curvi-linear association between age and the therapy prescribing outcome in question  
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Model 1.of table 7 tests the association between Framingham cardiovascular risk score and CTVB in men 
and women adjusting for age and age squared. Model 2 tests the association between Framingham 
cardiovascular risk score and CTVB in men and women adjusting for age, age squared and SIMD. Each 
regression co-efficient (B through to G) represents the difference in Framingham score between the given 
band and band A. The p-value in the first row of each table represents the significance of the overall 
associations. 
The analysis found that CTVB was a significant predictor of Framingham cardiovascular risk score in 
both men and women (Model 1) but according to the R-squared values that the addition of SIMD into the 
model (Model 2) improved its predictive value in women. In men CVTB alone was an independent 
predictor of cardiovascular risk and the model did not improve on addition of SIMD (Model 2).  The AIC 
values support this also where the addition of SIMD, moving from model 1 to model 2 increased the AIC 
value by 2 for men; thus demonstrating a weakening model fit. The AIC values for women within the 
same model comparison demonstrate massively improved model fit with the addition of SIMD. CTVB 
thus adds predictive power (over and above SIMD) of cardiovascular risk in men but not in women.  
CHAPTER 5: RESULTS, THE PREDICTIVE VALIDITY OF CTVB AS A MEASURE OF SEP 
IN THE SECONDARY PREVENTION OF CHD  
5.1 Secondary prevention population demographics 
 
Table 8 details the demographics of the secondary prevention population. The majority of individuals 
with CHD in Paisley at the recording point in 2009 were male (54.9%) and the male population was 
significantly younger than the female population. The majority of individuals with CHD are from council 
tax bands A and B. There is no other demographic information available on this population for ethical 
reasons. Based on an estimated population size the approximate prevalence of CHD in Paisley is 3.7%, 
which is similar to CHD prevalence recorded in primary care in other UK studies
243 (however this 
estimate is based on data from 12 of 13 GP practices in Paisley and with thus be higher if this data were 
available).  
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Table 8: Secondary prevention population demographics 
   Male Female 
Total   1,739 
(54.86) 
1,431 (45.14) 
Mean age  67.7 (2.91)  72.6 (3.12) 
CTVB A  398 (22.9)  314 (21.9) 
CTVB B  873 (50.2)  669 (46.8) 
CTVB C  199 (11.4)  158 (11.0) 
CTVB D  115 (6.6)  123 (8.6) 
CTVB E  85 (4.9)  108 (7.5) 
CTVB F  38 (2.2)  34 (2.4) 
CTVB GH  31 (1.8)  25 (1.7) 
Cases utilised: 3,170 
 
Assessing if there are any missing cases within the secondary prevention primary care extract is 
problematic. The extract is entirely of a binary nature, i.e. a “1” represents the presence of an appropriate 
value within the primary care risk factor recording field; thereby meaning that the risk factor review had 
taken place. Similarly for the therapies prescribing a “1” represents appropriate values in the therapies 
prescribed and review date primary care fields; thereby meaning that the therapies review had taken place 
and the given medication was prescribed. Where a “0” is returned, in both instances, it means that the 
relevant primary care fields did not contain any values and therefore the risk-factor review or therapies 
review had not taken place. It is indeterminate from the format of the extract whether a proportion of the 
“0” values are potentially missing cases; where the review had taken place but the values were not entered 
within the practice. However every effort was taken to ensure that this extract is accurate and the potential 
for missing cases (and determining the quantity of missing cases) is out with the control of the study. 
Given that the recording of risk factors and prescribing is financially incentivized the potential for 
missing cases is small.  
5.2 Distribution of risk factor monitoring in primary care by both CTVB and SIMD 
 
Figure 13 below shows that overall risk factor recording has risen dramatically over 1999-2009, 
especially after the introduction of the QOF in 2004:  
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Figure 14: Risk factor monitoring in men and women in Paisley with CHD excluding exception 
reporting of failure to attend review over 1999 to 2009 
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As described in the methods chapter this analysis does not include patients who have been recorded as not 
attending review who have been invited on at least three occasions during the reporting period and have 
been recorded under exception reporting. Analysis of the risk factor monitoring rates in 2009 showed that 
after exception reporting is removed none of the monitoring levels reached the QOF targets (detailed in 
figure. 4). Blood pressure recording shows that 72.8% of the secondary prevention population had at least 
one measure of this risk factor taken in 2009- 17.2% below the 90% QOF target. Cholesterol recording in 
2009 was 66.1%, some 23.9% below the QOF target. Smoking status monitoring was at 64% within the 
target population; 26% below the QOF target. The proportion of the target population having body mass 
index recorded in 2009 was 46%.  
Rates of risk factor monitoring for cholesterol, blood pressure, smoking status and body mass index 
within the secondary prevention population will now be analysed according to CTVB. Due to low 
numbers (as evidenced in the table within section 5.2) Bands G and H are combined throughout this 
analysis.    
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Table 9: Rates of Risk factor monitoring by CTVB in men and women in Paisley with CHD 
excluding exception reporting of failure to attend review in 2009 
CTVB A  B  C  D  E  F  GH 
Value of 
Housing* 
Up to 
£27,000 
£27,000 
to 
£35,000 
£35,000 
to 
£45,000 
£45,000 
to 
£58,000 
£58,000 
to 
£80,000 
£80,000 
to 
£106,000 
£106,000 
+ 
Cholesterol 490 
(68.8) 
919 
(59.6) 
280 
(78.4)  
168 
(70.6) 
147 
(76.2) 
62 (86.1)  45 (80.4) 
Blood Pressure  485 
(68.1) 
1168 
(75.8) 
267 
(74.8) 
181 
(76.1) 
142 
(73.6)  
57 (79.2)   41 (73.2) 
Smoking Status  440 
(61.8) 
984 
(63.8) 
217 
(60.8) 
147 
(61.8) 
132 
(68.4)  
54 (75.0)  44 (78.6) 
Body Mass 
Index 
287 
(40.3) 
696 
(45.1)  
180 
(50.4) 
116 
(48.7) 
79  (40.9) 47  (65.3) 32  (57.1) 
Cases utilised: 3,170 
 
Table 10: Regression output for risk factor monitoring by CTVB in men and women in Paisley with 
CHD excluding exception reporting of failure to attend review in 2009 
From regression, un-
adjusted 
From regression, adjusted 
for age, age-squared* and 
sex 
From regression, adjusted for 
age, age-squared*, sex and 
SIMD 
   P-value AIC  C-stat  P-value  AIC C-stat P-value AIC  C-stat 
Cholesterol 0.006  2854.9 0.55 0.007 2820.5 0.59 0.12  2814.3  0.6
Blood 
Pressure 
0.05 2906.3  0.54 0.01 3293.2 0.56 0.09  3276.5  0.58
Smoking 
Status 
0.03 3297.7  0.54 0.04 2802 0.63 0.04  2806.8  0.63
Body Mass 
Index 
0.03 3049.4  0.53 0.045 3047.1 0.55 0.4  3034.6  0.58
*age-squared term proved to have significant association with all therapies prescribing and was thus 
retained in adjusted models to account for the curvi-linear association between age and the therapy 
prescribing outcome in question 
 
Cases utilised: 3,170 
Table 6 above details the output of risk factor recording regression analysis. The table contains p-values, 
AIC values and C-statistic values. The values are presented under the three models like that of table 6. 
The findings of this analysis are that (using CTVB) socioeconomic inequalities in risk factor recording  
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are evident in the first two models but when SIMD is introduced in third model on smoking status 
remains significant. 
According to the p-values all risk factor proved to have significant association with CTVB in the 
unadjusted model. These associations tended to weaken slightly (but remained significant) when adjusting 
for age, age-squared and sex in the second model, with the exception of blood-pressure, where its p-value 
reduced from 0.05 (unadjusted) to 0.01 (adjusted).  
However based on the p-values, the addition of SIMD into the third model tends to weaken the 
independent contribution of CTVB with all risk factor recording (making the contribution insignificant) 
with the exception of smoking status, where it’s p-value remained un-changed after the introduction of 
SIMD into the regression model and still significant (0.04).  
The smaller AIC values in model 3 which includes age, sex, CTVB, SIMD compared to that of model 2 
including age, sex and CTVB indicates that SIMD is improving model fit. The exception to this is 
smoking status where AIC value increases from 2802.0 to 2806.8 moving from model 2 to 3. This 
demonstrates that CTVB has an independent contribution to smoking status recording. There is no 
increase in the c-statistic for smoking status recording moving from model 2 to 3, demonstrating that the 
addition of SIMD into the model adds no predictive power for smoking status recording. The c-statistic 
for the rest of the risk factors increase slightly over the same comparison further demonstrating the 
addition of SIMD improves predictive power.   
5.3 Distribution of secondary prevention therapies prescribing in men and women in Paisley with 
CHD excluding exception reporting of failure to attend review  
 
Figure 15 below shows secondary prevention therapies prescribing in primary care amongst the secondary 
prevention population over the period 1999 to 2009. All therapies have significantly increased over the 
recording period particularly at 2004. However all therapies prescribing are below QOF targets once 
selected exception reporting as detailed in the method section are removed. Analysis of 2009 data reveals 
that anti-platelet prescribing was at 72.3%, some 17.7% below the QOF target, beta-blocker prescribing 
was at 45%, 5% below the QOF target, ace-inhibitor prescribing was at 62.9%, some 7.1% below the 
QOF target, statin prescribing was at 53%- there are no specific targets for statin prescribing other than 
the 60% target of patients with cholesterol of 5.0 mmol/l.   
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Figure 15: secondary prevention therapies prescribing in men and women in Paisley with CHD 
excluding exception reporting of failure to attend review over the period 1999 to 2009 
 
Table 11: Rates of secondary prevention therapies prescribing by CTVB in men and women in 
Paisley with CHD excluding exception reporting of failure to attend review in 2009 
CTVB  A B C D E F  GH 
Value of 
Housing* 
Up to 
£27,000 
£27,000 
to 
£35,000 
£35,000 
to 
£45,000 
£45,000  
to 
£58,000 
£58,000 
to 
£80,000 
£80,000 to 
£106,000 
£106,000 + 
Ace-
inhibitor 
444 
(62.4) 
955 
(61.9) 
219 
(61.3)  
164 
(68.9) 
124 
(64.2) 
40 (55.6)  42 (75.0) 
Anti-
platelet 
533 
(74.9) 
1045 
(67.8)  
247 
(69.2) 
184 
(77.3) 
149 
(77.2)  
52 (72.2)   43 (76.8) 
Beta-
blocker 
324 
(45.5) 
646 
(41.9) 
201 
(56.3) 
94 (39.5)  105 
(54.4)  
40 (55.6)   37 (66.1)  
Statin 362 
(50.8) 
830 
(53.8) 
161 
(45.1) 
147 
(61.8) 
104 
(53.9) 
48 (66.7)  35 (62.5)  
Cases utilised: 3,170 
*based on 1991 value 
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Table 12: Regression output for secondary prevention therapies prescribing by CTVB in men and 
women in Paisley with CHD excluding exception reporting of failure to attend review in 2009 
From regression, un-
adjusted 
From regression, adjusted 
for age, age-squared* and 
sex 
From regression, adjusted for 
age, age-squared*, sex and 
SIMD 
   P-value AIC  C-stat  P-value  AIC  C-stat  P-value AIC  C-stat 
Ace-
inhibitor 
0.39 1247.6  0.55 0.7 1217.3 0.63 0.58  1214.5  0.65
Anti-
platelet 
0.56 1544.4  0.53 0.51 1463.7 0.67 0.73  1463.8  0.68
Beta-
blocker 
0.07 1281.9  0.56 0.11 1220.2 0.66 0.12  1226.2  0.69
Statin 0.04  1539.4  0.55 0.04 1437.1 0.69 0.02  1438.8  0.69
*age-squared term proved to have significant association with all therapies prescribing and was thus 
retained in adjusted models to account for the curvi-linear association between age and the therapy 
prescribing outcome in question 
Cases utilised: 3,170 
 
Table 11 above details the output of therapies prescribing regression analysis. The table contains p-values, 
AIC and C-statistic values. The values are presented under the three models like that of tables 6 and 9. 
The findings are that only Statin prescribing displayed significant socioeconomic (using CTVB as 
measure of SEP) variance, this was evidenced throughout the three models. 
According to the p-values, all therapies prescribing with the exception of statins (although beta-blockers 
were marginal (p=0.07)) proved to have insignificant associations with CTVB in the unadjusted model. 
These associations tended to remain unchanged when adjusting for age and age-squared in the second 
model, with the exception of ace-inhibitor, where its p-value increased from 0.39 to 0.70.   
Based on the p-values, the addition of SIMD into the third model tends to weaken the independent 
contribution of CTVB within anti-platelet and beta-blockers prescribing, but increases the contribution 
with ace-inhibitor and Statins. The independent contribution of CTVB with statin prescribing remained 
significant (p=0.02) in the third model adjusting for age, age-squared*, sex and SIMD, but was 
insignificant for ace-inhibitors (p=0.58). This indicates that CTVB has an independent contribution to 
statin prescribing, but has not for the rest of the therapies. 
The smaller AIC values in model 3 for ace‐inhibitor prescribing indicates that SIMD is improving model fit 
for this therapy prescribing rate. However the AIC values for the rest of the therapies tend to increase 
very slightly indicating that the addition of SIMD adds nothing to model fit. The c‐statistic for therapies  
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prescribing remained relatively unchanged moving from model 2 to 3 indicating little predictive power 
with the addition of SIMD to the model.  
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CHAPTER 6: DISCUSSION  
6.1 Revisiting the study aims 
 
The aims of the study were to examine the socioeconomic distribution of absolute cardiovascular risk and 
classical risk factors in an asymptomatic population and to explore inequalities in risk factor monitoring 
and therapies prescribing within primary care in an established CHD population. In both population 
analyses the overarching aim of the study concerns the predictive validity of CTVB as a surrogate marker 
of SEP and its strength of association within these analyses will be compared to SIMD- an established 
measure of SEP in Scotland. The analysis began by examining the association between CTVB and SIMD.  
 
6.2 Main findings of the study 
 
6.2.1 The predictive validity of CTVB as a marker of SEP in the primary prevention population 
 
The association between CTVB and SIMD was undertaken using data from the primary prevention 
population to establish the extent to which CTVB- the hypothesized marker of SEP correlated with a 
nationally established measure of SEP. The results of this analysis (p-value<0.0001, R
2=0.40) are almost 
identical to the association explored in another study between CTVB and the Jarman Index
133 (p-
value<0.0001, R
2= -0.42); CTVB increased as the Jarman Index reduces, thereby both moving in the 
direction of reducing deprivation. Thus findings from the present study support those of the Jarman study; 
that it is reasonable that CTVB is considered as a marker of SEP.  
Similar to well established literature in the field
187-225, the distribution of some cardiovascular risk factors 
in this study demonstrated significant socioeconomic variance; where individuals of lower SEP had worse 
risk factor profiles than those of higher SEP. Using CTVB as surrogate marker of SEP both HDL 
cholesterol and BMI levels displayed statistically significant socioeconomic variance in women but not 
men; however the association proved insignificant once the effects of SIMD were adjusted for. These 
findings are somewhat consistent with literature reviewed; whereby the inverse association between SEP 
and cholesterol is demonstrable but varied and somewhat unclear
202-206, However, the association between 
SEP and obesity in women but not men is consistent with the literature reviewed
223-225. 
Remarkably similar to another study
134 investigating CTVB as a surrogate marker of SEP in general 
practice, the socioeconomic distribution of current smokers according to CTVB was striking; representing 
a near perfect gradient where both men and women (p-value < 0.001) in the lowest value council tax band  
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(band A) had significantly higher rates of current smokers (49.94% and 40.14% respectively) compared to 
men and women in the highest value council tax band; band G (5.00% and 0% respectively). The 
association between CTVB and rates of current smokers remained after adjustment for both age, age-
squared and SIMD. The socioeconomic gradient seen in rates of current smokers in this study is 
consistent with well established literature in the area
216-219.  
Blood pressure, both systolic and diastolic did not vary significantly between council tax bands in either 
men or women in the present study. Interestingly, this is not consistent with the vast majority of literature 
in the field where blood pressure and SEP have a definite inverse relationship
207-210. 
Comparing the strength of association between CTVB and Framingham risk and SIMD and Framingham 
risk revealed some noteworthy results. Consistent with all studies reviewed Framingham risk has an 
inverse relationship with SEP
20; 179; 229; 232. In the present study CTVB had a significant association with 
Framingham scores in both men and women. However it was concluded that in women CTVB did not 
add predictive power over the association evidenced between SIMD and Framingham risk score. 
However in men adding CTVB did add predictive power over the association between SIMD and 
Framingham risk score. Hence, CTVB proved to have an independent association with Framingham risk 
in asymptomatic men (but not women) aged between 45 to 60 years.  
There are no studies examining the association of CTVB and asymptomatic cardiovascular risk factors or 
absolute risk with which to compare the findings of the present study. However CTVB’s independent 
association with Framingham risk in men and smoking rates in men and women are somewhat supportive 
with the conclusions of limited literature in the field; that CTVB is worthy of consideration as a marker of 
SEP in health research and may have utility ahead of aggregated or area-based measures of SEP
133-138. 
The present study’s findings are however  generally less convincing than those summarised in the 
literature review. The questionable accuracy of absolute measures of cardiovascular risk
234 casts caution 
on these results.  
Overall, the associations with cardiovascular risk factors and CTVB in the present study are weaker than 
the associations seen in other studies using established markers of SEP; income, education, occupation 
and other housing markers
61;64-66;83;91;92;102;103;187-225. Importantly the lack of significant variance in blood 
pressure between bands
207-210 casts doubt over CTVB as reliable marker of SEP in cardiovascular 
research.   
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6.2.2 The predictive validity of CTVB as a marker of SEP in the secondary prevention population 
 
Similar to literature reviewed, risk factor (cholesterol, blood pressure, BMI and smoking status) 
monitoring has increased dramatically over the period 1999 to 2009 in the present study
248;252. Again 
similar to the evidence reviewed; a marked rise is observed around 2004 when the QOF contract was 
introduced- thereby rewarding general practices for monitoring CHD patients’ risk factors and attaining 
targets within levels of risk factors. When removing exception reporting from the totals of risk factor 
recordings it is clear that actual risk factor monitoring levels seen in 2009 were below the QOF target 
levels. These methods adopted in the present study are identical to that of McLean et al
256 whereby the 
concepts of ‘payment quality’ versus ‘actual delivery quality’ in secondary prevention under the QOF are 
explored. By adopting this method the present study highlights a number of inequalities that may have 
been potentially ‘masked’ through current QOF exception reporting arrangements. 
Using CTVB as of the measure of SEP, significant socioeconomic variances in cholesterol, blood 
pressure, body mass index and smoking status were observed in model 2 of the regression analysis within 
the secondary prevention population. Socioeconomic inequalities in risk-factor monitoring are consistent 
with some
254; 256 but not all
258-260 of the literature reviewed. CTVB’s independent contribution to smoking 
status monitoring remained significant even when SIMD was introduced to the regression modelling in 
model 3. 
CTVB proved to have an independent contribution to the likelihood of Statin prescribing within the 
secondary prevention population. This contribution remained significant over the three models. CTVB did 
not have a significant independent contribution to prescribing rates within the remaining therapies.  
Reviewing the distribution of secondary prevention outcome variable rates across CTVB is crucial in 
interpreting the regression modelling analyses. Where CTVB’s significant independent contribution is 
established with secondary prevention outcomes variables it appears that higher (more affluent) council 
tax bands have higher rates of the outcome measures in question thus experiencing better care and 
treatment than the lower (more deprived) council tax bands. 
There are no studies with which to directly compare the use of CTVB as a marker of SEP in analyses 
exploring inequalities in risk factor recording and therapies prescribing in secondary prevention 
populations.   
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6.3 Implications of the main findings of the study for CHD prevention 
 
The synthesis of evidence in the literature review of the present study has raised important considerations 
within CHD primary prevention. In particular there is a paucity of reliable research or evaluation relating 
to the process of effective CHD primary prevention delivery. Reviewing the evidence identified a number 
of issues that make primary prevention studies challenging to compare and findings difficult to generalise. 
These include differences in the reporting of recruitment, enrolment, and retention information; 
inconsistencies in the use of terminology and reporting of physiological and behaviour measures and 
variations within comparable measures of SEP across studies, and the complexity of the literature which 
covers disparate samples of socio-demographic compositions representing different risks, different sub 
categories of cardiovascular disease and risk factors, definitions of risk and study types. 
 
Findings of this study support evidence that socioeconomic inequalities in asymptomatic cardiovascular 
risk persist. Socioeconomic inequalities in asymptomatic cardiovascular risk seen in this study are weaker 
than the established evidence but this is perhaps as a result of using CTVB as the marker of SEP as 
opposed to a validated measure of SEP. Overall, the socioeconomic inequalities in classical risk factors 
within the present study highlight the need for primary prevention interventions to effectively target and 
positively discriminate resource allocation in favour of deprived communities or individuals of lower 
SEP. This requires a substantial improvement in current evidence; specifically in identifying and 
engaging low SEP communities and individuals and improving intervention engagement, efficacy and 
outcomes within prevention strategies
16. Furthermore the socioeconomic gradients in risk factors 
(particularly smoking in the present study) and absolute risk suggest that the thrust of primary prevention 
activity in low SEP areas should remain on classical risk factors. This is especially true when considering 
the life course exposure to such risk within deprived communities
181; 182. A key challenge to public health 
is perhaps to remain focussed on effectively applying what is known already; in terms of reducing 
exposure to classical risk factors whilst continuing to further develop understanding of the disease 
through research into novel risk factors and the wider influences and determinants of CHD development.  
Interestingly female absolute risk showed equal association with CTVB and SIMD. This suggests that the 
female risk profile within the current study is influenced by contextual and compositional factors in equal 
measures. Male risk profiles, which show better model fit with CTVB than SIMD, in this study, appear to 
be more influenced by compositional, individual behavioural risk than on neighbourhood or area, 
contextual factors. This finding is consistent with the recently published 2011 Scottish Health Survey
290.  
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These gender differences have potentially interesting implications for the design of primary prevention 
interventions. Research to date has not heavily distinguished between gender differences in contextual 
and compositional influences on risk.  
Implementation of the QOF has received mixed reviews within the literature as to its impacts on CHD 
secondary prevention and equity of service delivery. The very existence of exception reporting 
acknowledges some individuals with CHD are potentially harder to engage in secondary prevention care 
and treatment than others. A criticism of the QOF is thus that it does not recognise this in terms of 
remuneration.  
A fairer system would be to allocate additional remuneration for those sub-groups of CHD populations 
which are less likely to be optimally managed or cared for. This revision would mean that the greater 
effort on the part of the GP to engage with such sub-groups is rewarded with greater QOF payment. This 
decision may be unpopular with GPs serving affluent areas, for whom this could potentially mean less 
payment than peers serving more deprived areas. However equity of care as a principle must surely be of 
a higher priority for the GMS than the individual financial gain of GPs. It is questionable whether health 
care should ever be incentivised
253. However the massive increases in risk factor monitoring and 
secondary prevention therapies prescribing evidenced in this (and other studies
257;261;263;264) after the 
introduction of the QOF are striking- the QOF has improved levels of care overall.  
The findings of this study are important in that they accurately characterise sections of the CHD 
population within the sample to the household level that are being underserved by current QOF 
arrangements. By adopting the methods outlined in the present study demonstrates that actual (versus 
paid) QOF risk factor monitoring and prescribing targets were not met and some inequalities in care and 
treatment persist in lower values council tax bands.  
The methods adopted in the present study may have seen individuals exempted for reasons of frailty 
recorded and counted as a non-attendance; the difference in coding being inconsequential to QOF 
payment. Frailty increases with age, thus perhaps explaining the apparent age inequalities. This theory 
was supported by NHS IT support staff working with QOF data within the present study, but has not been 
explored within the literature. On further consideration this does not detract from the findings; if the 
patient is too frail to attend the practice then under duty of care the GP must perform the review by some 
other means.  
The socioeconomic inequalities evidenced in risk-factor monitoring and statin prescribing within the 
present study is striking and is an important finding. In pragmatic terms there is no room for  
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complacency;  individuals of lower SEP and higher risk of a recurrent cardiovascular event are being sub-
optimally managed. Greater socio-demographic scrutiny must be placed on exception reporting. In the 
longer-term, based on the findings of this study (and others
247) the current arrangements of the QOF are 
likely to see Tudor-Hart’s inverse care law persist.   
6.4 The utility of CTVB as a surrogate marker of SEP 
 
Irrespective of whether CTVB can be considered as a satisfactory surrogate marker of SEP it has many 
appealing characteristics which validate its consideration. Beale et al
133-136 argue that CTVB is official, is 
‘instituted and maintained’ by the Government for its own discreet purpose- it can therefore be considered 
as independent of any health debate and therefore a truly objective measure.  
Beale further argues that CTVB is also ‘universal, comprehensive and stable’- council tax data is readily 
available online and is complete, without fail for every UK property; all property values (including new 
and extended properties) are generated as of 1991 values ensuring consistency and reliability of values 
across all of the country.  
As council tax data is available to the household level it could be argued that it is free of the ‘ecological 
fallacy’
133;135 which has been described as inherent in aggregated geographically defined data which can 
never be truly representative of all individuals residing there in. CTVB theoretically is not prone therefore 
to the underestimation of deprivation influence as is often argued is the case for ecological measures. 
CTVB can also be obtained and accessed without intrusion to the study participants which has great 
advantage, saving time and money, and increasing data quality, especially when working on large scale 
projects. Council tax bands are also incredibly easy to work with in epidemiological studies; a simple 
categorical variable, easily summarized and aggregated and trouble-free for use in statistical analysis.  
Whilst CTVB appears to have many strengths as a marker of SEP, data linkage within this study proved 
problematic for approximately 18% in both the primary and secondary prevention populations. One of the 
main reasons for this was because in the region of 40% of Paisley properties are flats and thus up to 12 
individual properties may share the same postcode, but vary in council tax band. For example a block of 
flats built in Paisley’s West-end vary in accommodation size from one bedroom flats (band A) to  three 
bedroom flats (band D), thus the full address was utilized in the data linkage which was entirely 
dependant on how, or how well address data were recorded in health records (there are several ways to 
record ‘Flat 2/1’, i.e. ‘2/1’, ‘2-1’, ‘Apt 2/1’, ‘Flat 2, 1st floor’ etc). Algorithms developed by the Health 
Information and Technology Development team performing extracts for this study enabled the majority of  
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the records to be linked electronically, even when the full address did not merge initially. This scaled 
down the unmerged data to around 11% which still took approximately 40 hours to match records 
manually.  
It also became apparent that CTVB actually has significant shortcomings as a measure of SEP in terms of 
its ‘universality’ and ‘completeness’ as described by Beale et al
133-136; a fundamental issue was 
encountered during data linkage. Measures of SEP are assessed on their ability to measure material 
resource and circumstance; thus impacting on one’s ability to purchase health promoting commodities 
and avoid exposure to risk factors. Using council tax bands as a marker of SEP fails to recognise the 
inherent difficult of accurately assigning a suitable CTVB to individuals who are renting properties. By 
way of a real-life example from the present study; a tenement town-house in Paisley town centre was 
assigned council tax band H (based purely on the value of this substantial property) when on further 
investigating it transpires that the property is in fact a five bedroom bedsit with five tenants residing there. 
Thus all five tenants were allocated council tax band H- which is highly unlikely to be representative of 
their material resource and circumstance. Even in individual properties which are rented it is unlikely that 
the CTVB will provide an accurate measure of SEP for tenants, perhaps tending to overestimate SEP, 
compared to its utility as a marker of SEP for home owners. The potential for anomalous allocation of 
CTVB in the rental housing market represents a serious shortcoming of CTVB as a measure of SEP. This 
finding was briefly mentioned by Fone et al
137 but was not discussed. Furthermore this finding has not 
been highlighted in the rest of the studies outlined in the literature exploring the potential of CTVB as a 
marker of SEP
133-136; 138.  
The predictive validity of CTVB is further diminished when considering the price increase of property in 
recent years. Whilst CTVB attempts to recalculate housing value to 1991 levels (ensuring equity of 
CTVB classification over time) it does not take cognisance of the proportion of household income which 
is outgoing on mortgage within the same council tax band. Due to exorbitant price increases in the 
housing market since the late 1990s it is likely that the CTVB of a home purchased in 1995 represents 
significantly less proportionate mortgage outgoings for the same home purchased in 2010. Thus the 
amount of disposable income under the same CTVB might be hugely varied, thereby leading to inaccurate 
or incomparable allocation of SEP using CTVB.   
An appealing characteristic of CTVB is that it is available at a household level and thus is close to an 
individual level measure of SEP. The independent contribution of CTVB to absolute risk, some risk 
factors, risk factor monitoring rates and statin prescribing rates suggests some merit in seeking to move 
from aggregated forms of SEP. When contextualising the findings from this study in the current literature  
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it could be argued that the debate concerning area-based/individual measures of SEP has reached 
theoretical saturation. From the papers reviewed
112-132 it would appear that either compositional or 
contextual influences on health are supported to the detraction of the other. Furthermore the term 
‘ecological fallacy' appears over-used and misused in the literature whenever compositional influences on 
health come to the fore in a given study.  
To this end perhaps the challenge to epidemiological research is to acknowledge that both compositional 
and contextual influences on health and disease co-exist; thus, instead the challenge is to better 
understand or conceptualise the causal mechanisms or pathways which underpin and reinforce these 
influences on health behaviours and outcomes, particularly amongst individuals of lower SEP where 
inequalities there in exist. This greater understanding and insight into why and how health damaging 
behaviours are adopted would enable public health in general and prevention strategies in particular to 
develop more effective, nuanced approaches to prevention intervention or programme design.  
The findings of this study suggest that the potential for CTVB to be immediately used as a surrogate 
marker of SEP in health research is limited. The most applicable finding from this study is perhaps the 
independent contribution CTVB has in predicting current smoking rates and smoking status monitoring. 
CTVB may add value to existing measures of SEP in the design and coordination of population based 
smoking cessation campaigns or services especially amongst asymptomatic populations where smoking 
status is not known across the complete population.  
6.5 Strengths of the present study 
 
The present study is completely novel and the findings are potentially useful and interesting to a wide 
range of health professionals, from health improvement officers to policy makers, planners and 
epidemiologists. The scope of the study is extremely ambitious; synthesising many strands of, at times, 
diverse evidence and literature in a coherent, structured way.  
The analysis covers both primary and secondary prevention populations and the findings highlight 
persistent and important inequalities which are of burning relevance to the development and delivery of 
CHD prevention services and interventions in Scotland and beyond. The findings and discussion sections 
highlight important issues in relation to the use of CTVB as a surrogate marker of SEP. Current evidence 
in this field has barely touched on the issues highlighted in the present study.   
 
88
 
6.6 Limitations of the present study 
 
It should be recognized that the SIMD contains a health domain which in part may be confounding in 
terms of its co-linearity with cardiovascular risk variables. Ideally the health domain should have been 
removed from the SIMD prior to the analysis; however this was not possible from the original data 
extract. Similarly the multi-co linearity in the primary prevention regression model (SIMD and CVTB are 
reasonably strongly correlated) is potentially a limitation within the analyses.  
The validity of the Framingham score as well as total and HDL cholesterol levels recorded in the primary 
prevention population is compromised by the cholesterol measure being taken in a non-fasting state. 
Whilst some studies have shown that lipid profiles change only slightly during fasting versus non-fasting 
measurement, it is recognized that the most accurate tests are performed under fasting conditions. 
Both the primary and secondary prevention populations’ sampling framework was based entirely on 
patients registered with a Paisley GP. As such an indeterminate proportion of patients fitting the selection 
criteria, but not registered with a GP will have been excluded from this study.  
6.7 Recommendations from the study 
 
Findings from this study are important and have relevant implications for current approaches to 
prevention of CHD in the UK. Findings from the study support: 
  That in terms of CHD prevention policy; the potential of CTVB as a surrogate marker of SEP 
should be noted and explored in further research.  
  That CHD primary prevention resources should continue to be weighted towards areas or 
individuals of lower SEP where exposure to classical risk factors are higher over the life-course. 
  That future research should recognise that both compositional and contextual influences on health 
co-exist; for CHD prevention arguably the priority is not to establish which has the greater 
influence but to investigate and conceptualise the causal mechanisms of both influences which 
underpin and reinforce cardio-damaging behaviours particularly amongst individuals of lower 
SEP  
 
89
  That the potential of exception reporting to ‘mask’ socioeconomic and other inequalities in CHD 
secondary prevention care and treatment must be recognised and investigated on a larger scale 
and in more detail by the GMS. 
  Further QOF investigation and research should adopt the methods outlined in the present study 
where exception reporting is removed leaving actual care and treatment delivery as opposed to 
care and treatment payments. 
6.8 Conclusions 
 
Based on the findings of the present study CTVB has limited scope as a surrogate marker of SEP in the 
primary and secondary prevention of CHD in the UK. Some findings of the study are noteworthy 
however the reliability of CTVB as a marker of SEP must be investigated further. Contrary to CTVB 
literature to date, this study encountered difficulties in the linkage of CTVB to health records and 
identified a major concern in relation to CTVB misclassifying the SEP of individuals who are not home 
owners; potentially overestimating individual SEP of those renting, especially within homes of multiple 
occupancy. The consistency and accuracy of CTVB as a measure of SEP is also questionable given the 
increase in housing price in recent years.  
The present study demonstrates that socioeconomic disparities and inequalities exist within risk profiles 
of the asymptomatic population (primary prevention) and the care and treatment of the established CHD 
population (secondary prevention). The former reinforcing approaches which target the reduction of 
classical risk factors in high risk populations, the latter having strong implications for the delivery of 
secondary prevention under the GMS QOF within Primary Care in Scotland.    
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Appendix C: GP consent letter 
Greater Glasgow and Clyde NHS Board  
 
 
 
 
 
            
Dear Practice 
IMPLEMENTATION OF CORONARY HEART DISEASE UNMET NEED PROJECT 
 
As part of Phase 2 of Have a Heart Paisley (HaHP) it was agreed that data relating to Coronary Heart 
Disease (CHD) would be routinely extracted from your practice to populate HaHP’s Chronic Disease 
Register (CDR). Building on the work of Have a Heart, Greater Glasgow and Clyde NHS Board in 
collaboration with the department of Public Health and Health Policy at the University of Glasgow are 
conducting research into unmet need in CHD within Paisley.   
The purpose of the study is to explore and describe the determinants of unmet need in Coronary Heart 
Disease (CHD) risk, care and provision of services within Paisley. This study has been approved by the 
South Greater Glasgow & Clyde Research Ethics Committee and the NHS Greater Glasgow & Clyde 
Caldicott Guardian. The study is funded by NHS Greater Glasgow & Clyde.  
As part of this research the CDR is being upgraded and updated. The data items required for the CDR are 
the same as those already routinely extracted from your practice for Keep Well and Local Enhanced 
Development 
Department 
Westward House 
13 St James Street 
Paisley  
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Services (LES).  All patient data analysed at the University of Glasgow will be at the population level and 
the data will be made anonymous and non-identifiable. 
We would be grateful if you could please complete the attached form if you agree that data from your 
practice can be used in this study. 
If you have any questions in relation to the unmet need research please contact either Dr Iain Findlay, 
Consultant Physician and Cardiologist at the Royal Alexandra Hospital, Paisley, email: 
iain.findlay@rah.scot.nhs.uk or Dr Kate MacIntyre, Senior Clinical Lecturer in Chronic Disease 
Epidemiology/Honorary Consultant in Public Health Medicine, at the University of Glasgow, Section of 
Public Health and Health Policy, email: k.macintyre@clinmed.gla.ac.uk 
Unmet Need Study 
I have read the accompanying letter and wish to approve the use of Keep Well and LES data extracted 
from my practice for the stated purpose of the Unmet Need research study. 
 
Practice Code:   
 
Practice Address:   
 
Telephone No:     
 
Signature: ………………………………………………………………………… 
 
NAME (IN BLOCK)  …………………………………………………………… 
 
Position …………………………………………….  Date …………………..  
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----------------------------------------------------------------------------------------------------------------- 
 
1.  Planned Date of Installation: TBC. No user intervention is required.  
 
2.  We will telephone the practice following the install to confirm that the server installation has 
been successful. 
 
   Who would you prefer us to ask for: ………………………………………………… 
------------------------------------------------------------------------------------------------------- 
Please fax back to:    Development Dept.              FAX #: 
        Westward House      0141 843 2762  
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Appendix D: Have a Heart Paisley CDR awareness raising and ‘Opt out’ form 
  
 
98
  
 
99
References 
 
 1.    The Scottish Government. Better Coronary Heart Disease and Stroke Care - a consultation 
document 2008. [http://www.scotland.gov.uk/Resource/Doc/233941/0064057.pdf]. The Scottish 
Government 2008. 
 2.    PYÖRÄLÄ K, DE BACKER G, GRAHAM I, POOLE-WILSON P, and WOOD D. Prevention 
of coronary heart disease in clinical practice: Recommendations of the Task Force of the 
European Society of Cardiology, European Atherosclerosis Society and European Society of 
Hypertension. Eur Heart J (1994) 15(10): 1300-1331. 
 3.    Yusuf S. Preventing Vascular Events Due to Elevated Blood Pressure. Circulation 
2006;113:2166-8. 
 4.    The Scottish Government. The Coronary Heart Disease and Stroke Strategy for Scotland 
2004. [http://www.scotland.gov.uk/Resource/Doc/30859/0012660.pdf]. The Scottish Government 
2004. 
 5.    Marmot MG, Kogevinas M. Social/Economic Status and Disease. Annual Review of Public 
Health 1987;Vol. 8: 111-135. 
 6.    Loucks EB, Lynch JW, Pilote L, Fuhrer R, Almeida ND, Richard H et al. Life-Course 
Socioeconomic Position and Incidence of Coronary Heart Disease. Am.J.Epidemiol. 
2009;169:829-36. 
 7.    Fiscella K, Franks P, Gold MR, Clancy CM. Inequality in Quality: Addressing Socioeconomic, 
Racial, and Ethnic Disparities in Health Care. JAMA 2000;283:2579-84. 
 8.    Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C et al. Emerging Risk Factors 
for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. 
Preventive Services Task Force. Annals of Internal Medicine 2009;151:496-507. 
 9.    Beaglehole R,.Magnus P. The search for new risk factors for coronary heart disease: 
occupational therapy for epidemiologists? Int.J.Epidemiol. 2002;31:1117-22. 
 10.    Knight G. Measures of Socioeconomic Status. The Canadian Journal of Sociology 1984 
9:2:234-236  
 11.    MacIntyre S. Equally Well: Report of the Ministerial Task Force on Health Inequalities, 
Briefing paper. The Scottish Government 2008. 
 12.    Pickett KE, Pearl M. Multilevel analyses of neighbourhood socioeconomic context and health 
outcomes: a critical review. Journal of Epidemiology and Community Health 2001;55:111-22. 
 13.    Diez Roux AV. Investigating Neighborhood and Area Effects on Health. Am J Public Health 
2001;91:1783-9.  
 
100
 14.    Sundquist K, Malmstrom M, Johansson SE. Neighbourhood deprivation and incidence of 
coronary heart disease: a multilevel study of 2.6 million women and men in Sweden. Journal 
of Epidemiology and Community Health 2004;58:71-7. 
 15.    Pocock J, Thompson S. Primary prevention trials in cardiovascular disease. Journal of 
Epidemiology and Community Health 1990, 44:3-6  
 16.   Harkins C, Shaw R, Gillies M, Sloan H, MacIntyre K, Scoular A et al. Overcoming barriers to 
engaging socio-economically disadvantaged populations in CHD primary prevention: a 
qualitative study. BMC Public Health 2010;10:391. 
 17.    Rejineveld SA. The impact of individual and area characteristics on urban socioeconomic 
differences in health and smoking. Int.J.Epidemiol. 1998;27:33-40. 
 18.    Hirsch AT,.Folsom AR. The Continuum of Risk: Vascular Pathophysiology, Function, and 
Structure. Circulation 2004;110:2774-7. 
 19.    Blankstein R,.Ferencik M. The vulnerable plaque: Can it be detected with Cardiac CT? 
Atherosclerosis 2010;211:386-9. 
 20.    Mora S, Redberg RF, Sharrett AR, Blumenthal RS. Enhanced Risk Assessment in 
Asymptomatic Individuals With Exercise Testing and Framingham Risk Scores. Circulation 
2005;112:1566-72. 
 21.    Wilson PWF, Hoeg JM, D'Agostino RB, Silbershatz H, Belanger AM, Poehlmann H et al. 
Cumulative Effects of High Cholesterol Levels, High Blood Pressure, and Cigarette 
Smoking on Carotid Stenosis. New England Journal of Medicine 2009;337:516-22. 
 22.    Davies SW. Clinical presentation and diagnosis of coronary artery disease: stable angina. Br 
Med Bull 2001;59:17-27. 
 23.    Berger PB, Ellis SG, Holmes DR, Jr., Granger CB, Criger DA, Betriu A et al. Relationship 
Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in 
Patients With Acute Myocardial Infarction : Results From the Global Use of Strategies to 
Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) Trial. Circulation 
1999;100:14-20. 
 24.    Egede LE, Zheng D. Modifiable Cardiovascular Risk Factors in Adults With Diabetes: 
Prevalence and Missed Opportunities for Physician Counseling. Arch Intern Med. 
2002;162(4):427-433 
 25.    Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary 
heart disease in clinical practice. Summary of Recommendations of the Second joint Task 
Force of European and other Societies on Coronary Prevention. The European Journal of 
General Practice 1999;5:154-61. 
 26.    Reddy KS. Cardiovascular Disease in Non-Western Countries. New England Journal of 
Medicine 2009;350:2438-40.  
 
101
 27.    Reddy KS, Yusuf S. Emerging Epidemic of Cardiovascular Disease in Developing Countries. 
Circulation 1998;97:596-601. 
 28.    World Health Organization. The world health report 2003 - shaping the future. World Health 
Organization 2003. 
 29.    Thom TJ, Epstein FH. Heart disease, cancer, and stroke mortality trends and their 
interrelations. An international perspective. Circulation 1994;90:574-82. 
 30.    Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E. Contribution of 
trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 
10-year results from 37 WHO MONICA Project populations. The Lancet 1999;353:1547-57. 
 31.    Zatonski W, Campos H, Willett W. Rapid declines in coronary heart disease mortality in 
Eastern Europe are associated with increased consumption of oils rich in alpha-linolenic 
acid. European Journal of Epidemiology 2008;23:3-10. 
 32.    Zatonski WA, Willett W. Changes in dietary fat and declining coronary heart disease in 
Poland: population based study. BMJ 2005;331:187-8. 
 33.    Bhopal R, Hayes L, White M, Unwin N, Harland J, Ayis S et al. Ethnic and socio-economic 
inequalities in coronary heart disease, diabetes and risk factors in Europeans and South 
Asians. J Public Health 2002;24:95-105. 
 34.    Marmot M, Socioeconomic Determinants of CHD Mortality. Int. J. Epidemiol. 1989 18(1): 
196-202  
 35.    Chandola T. Social class differences in mortality using the new UK National Statistics Socio-
Economic Classification. Social Science & Medicine 2000;50:641-9. 
 36.    Marmot MG. Social determinants of health. World Health Organization International 2006. 
 37.    The Scottish Government. Equally Well: Report of the Ministerial Task Force, 
http://www.scotland.gov.uk/Publications/2008/06/25104032/12. The Scottish Government 
2008. 
 38.    The British Heart Foundation. Uk Heart Stats, 
http://www.heartstats.org/datapage.asp?id=3668. British Heart Foundation 2007. 
 39.    Grundy SM. Primary Prevention of Coronary Heart Disease : Integrating Risk Assessment 
With Intervention. Circulation 1999;100:988-98. 
 40.    Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al. AHA Guidelines for 
Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel 
Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other 
Atherosclerotic Vascular Diseases. Circulation 2002;106:388-91. 
 41.    Smith SC, Jr., Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K et al. AHA/ACC 
Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic 
Cardiovascular Disease: 2001 Update: A Statement for Healthcare Professionals From the  
 
102
American Heart Association and the American College of Cardiology. Circulation 
2001;104:1577-9. 
 42.    Smith SC, Jr., Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ et al. AHA consensus 
panel statement. Preventing heart attack and death in patients with coronary disease. The 
Secondary Prevention Panel. J Am Coll Cardiol 1995;26:292-4. 
 43.    Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24 431 patients with coronary 
heart disease: survey in primary care. BMJ 2001;322:1463  
 44.    MacIntyre K, Pell JP,  Morrison CE. Is the prevalence of coronary heart disease falling in 
British men? J Epidemiol Community Health 2002;56:404. 
 45.    Alpert JS, Coronary heart disease: where have we been and where are we going? The Lancet 
1999, 353,9164;1540-1541,  
 46.    Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment 
and risk factor changes to the decline in coronary heart disease mortality in Scotland 
between 1975 and 1994. Heart 1999;81:380-6. 
 47.    Galobardes B, Lynch J, Smith GD. Measuring socioeconomic position in health research. Br 
Med Bull 2007;81-82:21-37. 
 48.    Kaplan GA. Going Back To Understand the Future: Socioeconomic Position and Survival 
after Myocardial Infarction. Annals of Internal Medicine 2006;144:137-9. 
 49.    Ljung R,.Hallqvist J. SOCIOECONOMIC POSITION, CLUSTERING OF RISK 
FACTORS, AND THE RISK OF MYOCARDIAL INFARCTION. Am J Public Health 
2007;97:1927-8. 
 50.    Singh-Manoux A, Clarke P, Marmot M. Multiple measures of socio-economic position and 
psychosocial health: proximal and distal measures. Int.J.Epidemiol. 2002;31:1192-9. 
 51.    Liberatos P, Link BG. The measurement of social class in epidemiology.  Epidemiol Rev 
1988;10:87-121 1988. 
 52.    Beebe-Dimmer J, Lynch JW, Turrell G, Lustgarten S, Raghunathan T, Kaplan GA. Childhood 
and Adult Socioeconomic Conditions and 31-Year Mortality Risk in Women. 
Am.J.Epidemiol. 2004;159:481-90. 
 53.    Davey Smith G, Hart C, Hole D, MacKinnon P, Gillis C, Watt G et al. Education and 
occupational social class: which is the more important indicator of mortality risk? Journal 
of Epidemiology and Community Health 1998;52:153-60. 
 54.    White IR, Blane D, Morris JN, Mourouga P. Educational attainment, deprivation, affluence 
and self reported health in Britain: a cross sectional study. J Epidemiol Community Health 
1999;53:535-41. 1999.  
 
103
 55.    Geyer S, Hemström O, Peter R, Vågerö D. Education, income, and occupational class cannot 
be used interchangeably in social epidemiology. Empirical evidence against a common 
practice. Journal of Epidemiology and Community Health 2006;60:804-10. 
 56.    Lawlor DA, Ebrahim S, Davey Smith G. Adverse socioeconomic position across the lifecourse 
increases coronary heart disease risk cumulatively: findings from the British womens’ heart 
and health study. Journal of Epidemiology and Community Health 2005;59:785-93. 
 57.    Kelleher J. Cultural literacy and health.  Epidemiology 2002;13:497-500. 2002. 
 58.    Baker DW, Parker RM, Williams MV, Clark WS, Nurss J. The relationship of patient reading 
ability to self-reported health and use of health services. Am J Public Health 1997;87:1027-
30. 
 59.    Davey Smith G, Blane D, Bartley M.  Explanations for socio-economic differentials in 
mortality. Evidence from Britain and elsewhere.  Eur J Public Health 1994;4:131-44 1994. 
 60.    Hadden WC. The use of educational attainment as an indicator of socioeconomic position.  
Am J Public Health 1996;86:1525-6. 
 61.    Howden-Chapman P. Housing standards: a glossary of housing and health. Journal of 
Epidemiology and Community Health 2004;58:162-8. 
 62.    Kaplan GA,.Keil JE. Socioeconomic factors and cardiovascular disease: a review of the 
literature. Circulation 1993;88:1973-98. 
 63.    Woodward M, Shewry MC, Cairns S.Smith, Tunstall-Pedoe H. Social status and coronary 
heart disease: Results from the Scottish heart health study. Preventive Medicine 1992;21:136-
48. 
 64.    Shaw M. Housing and public health.  Annu Rev Public Health2004;25:397-418. 
 65.    Macintyre S, Ellaway A, Der G, Ford G, Hunt K. Do housing tenure and car access predict 
health because they are simply markers of income or self esteem? A Scottish study. Journal 
of Epidemiology and Community Health 1998;52:657-64. 
 66.    Macintyre S, Hiscock R, Kearns A, Ellaway A. Housing tenure and car access: further 
exploration of the nature of their relations with health in a UK setting. Journal of 
Epidemiology and Community Health 2001;55:330-1. 
 67.    Goddard M,.Smith P. Equity of access to health care services: : Theory and evidence from 
the UK. Social Science & Medicine 2001;53:1149-62. 
 68.    Rose D, Richards R. Food store access and household fruit and vegetable use among 
participants in the US Food Stamp Program. Public Health Nutrition 2004;7:1081-8. 
 69.    Asthana SH, Peal JB. Rural deprivation and service need: a review of the literature and an 
assessment of indicators for rural service planning. Bristol: South West Public Health 
Observatory. South West Public Health Observatory, 2002. 
  
 
104
 70.    Kuate-Defo B. Determinants of infant and early childhood mortality in Cameroon: the role 
of socioeconomic factors, housing characteristics, and immunization status.  Soc Biol 
1994;41:181-211. 2010. 
 71.    Banguero H. Socioeconomic factors associated with malaria in Colombia.  Soc Sci Med 
1984;19:1099-104. 1984. 
 72.    Galobardes B, Morabia A. Measuring the habitat as an indicator of socioeconomic position: 
methodology and its association with hypertension. Journal of Epidemiology and Community 
Health 2003;57:248-53. 
 73.    Galobardes B, Lynch J, Smith GD. Measuring socioeconomic position in health research. Br 
Med Bull 2007;81-82:21-37. 
 74.    Galobardes B, Shaw M, Lawlor DA, Lynch JW, Davey Smith G. Indicators of socioeconomic 
position (part 2). Journal of Epidemiology and Community Health 2006;60:95-101. 
 75.    Howe LD, Hargreaves JR, Huttly SR. Issues in the construction of wealth indices for the 
measurement of socio-economic position in low-income countries. Emerg Themes Epidemiol. 
2008 30;5:3. 
 76.    Lynch J KG. Socioeconomic position. Social epidemiology.1st ed.Oxford: Oxford University 
Press, 2000:13-35 2000. 
 77.    Lahelma E, Martikainen P, Laaksonen M, Aittomäki A. Pathways between socioeconomic 
determinants of health. Journal of Epidemiology and Community Health 2004;58:327-32. 
 78.    Braveman PA, Cubbin C, Egerter S, Chideya S,  Marchi KS, Metzler M, Posner S. 
Socioeconomic Status in Health Research: One Size Does Not Fit All.  JAMA. 
2005;294(22):2879-2888. 
 79.    Maty SC, Everson-Rose SA, Haan MN, Raghunathan TE, and Kaplan GA. Education, income, 
occupation, and the 34-year incidence (1965–99) of Type 2 diabetes in the Alameda County 
Study. Int. J. Epidemiol. 2005. 34(6): 1274-1281 
 80.    Ecob R DSG. Income and health: what is the nature of the relationship? Soc Sci Med 
1999;48:693-705. 1999. 
 81.    McDonough P, Duncan GJ, Williams D, House J. Income dynamics and adult mortality in the 
United States, 1972 through 1989. Am J Public Health 1997;87:1476-83. 
 82.    Turrell G. Income non-reporting: implications for health inequalities research. Journal of 
Epidemiology and Community Health 2000;54:207-14. 
 83.    Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how 
education, income, and occupation contribute to risk factors for cardiovascular disease. Am 
J Public Health 1992;82:816-20.  
 
105
 84.    Ranjit N, Diez-Roux AV, Shea S, Cushman M, Ni H, Seeman T. Socioeconomic Position, 
Race/Ethnicity, and Inflammation in the Multi-Ethnic Study of Atherosclerosis. Circulation 
2007;116:2383-90. 
 85.    Charlton, B. G. and White, M. Living on the margin: a salutogenic model for socio-economic 
differentials in health. Public health 109(4), 235-243. 7-1-1995.  
 86.    Lawlor DA, Ebrahim S, Davey Smith G. Adverse socioeconomic position across the lifecourse 
increases coronary heart disease risk cumulatively: findings from the British women’s heart 
and health study. Journal of Epidemiology and Community Health 2005;59:785-93. 
 87.    Evans D, Hebert LE, Beckett LA, Scherr PA, Albert MA, Chown MJ et al. Education and Other 
Measures of Socioeconomic Status and Risk of Incident Alzheimer Disease in a Defined 
Population of Older Persons. Arch Neurol. 1997;54(11):1399-1405 
 88.    Gregorio DI, Walsh SJ, Paturzo D. The effects of occupation-based social position on 
mortality in a large American cohort. Am J Public Health 1997;87:1472-5. 
 89.    Marmot MG, Shipley MJ. Do socioeconomic differences in mortality persist after retirement? 
25 Year follow up of civil servants from the first Whitehall study. BMJ 1996;313:1177-80. 
 90.    Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R. Geocoding and 
Monitoring of US Socioeconomic Inequalities in Mortality and Cancer Incidence: Does the 
Choice of Area-based Measure and Geographic Level Matter? Am.J.Epidemiol. 
2002;156:471-82. 
 91.    Winkleby, M A, Jatulis, D E, Frank, E, Fortmann, S P. Socioeconomic status and health: how 
education, income, and occupation contribute to risk factors for cardiovascular disease. Am 
J Public Health 1992 82: 816-820 
 92.    Maty SC, Everson-Rose SA, Haan MN, Raghunathan TE, Kaplan GA. Education, income, 
occupation, and the 34-year incidence of Type 2 diabetes in the Alameda County Study. 
Int.J.Epidemiol. 2005;34:1274-81. 
 93.    Bennett GG, Wolin KY, James SA. Lifecourse Socioeconomic Position and Weight Change 
among Blacks: The Pitt County Study. Obesity 2007;15:172. 
 94.    Artazcoz La,.Rueda S. Social inequalities in health among the elderly: a challenge for public 
health research. Journal of Epidemiology and Community Health 2007;61:466-7. 
 95.    Marmot MG, Shipley MJ, Hemingway H, Head J, Brunner EJ. Biological and behavioural 
explanations of social inequalities in coronary heart disease: the Whitehall II study. 
Diabetologia 2008;51:1980-8. 
 96.    Marmot MG, Stansfeld S, Patel C, North F, Head J, White I. Health inequalities among British 
civil servants: the Whitehall II study.  The Lancet. 1991; 337:8754: 1387-1393  
 97.    Lynch, J. W. Kaplan, G. A. Socioeconomic Position. In: Berkman and Kawachi, Social 
Epidemiology, 2000, pp. 13-35 Oxford University Press  
 
106
 98.    Duncan GJ, Daly MC, McDonough P, Williams DR. Optimal Indicators of Socioeconomic 
Status for Health Research. Am J Public Health 2002 92: 1151-1157 
 99.    Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Speizer FE et al. Prospective 
Study of Shift Work and Risk of Coronary Heart Disease in Women. Circulation 
1995;92:3178-82. 
 100.   ADLER1 NE, OSTROVE JM. Socioeconomic Status and Health: What We Know and What 
We Don't. Annals of the New York Academy of Sciences. Volume 896, 3-15, 1999 
 101.   Martikainen P,.Valkonen T. Bias related to the exclusion of the economically inactive in 
studies on social class differences in mortality. Int.J.Epidemiol. 1999;28:899-904. 
 102.   Miech RA, Hauser RM. Socioeconomic Status and Health at Midlife: A Comparison of 
Educational Attainment with Occupation-Based Indicators. Annals of Epidemiology. 2001; 
11:2;75-84. 
 103.   Wilkinson RG. Income distribution and life expectancy. British Medical Journal 
1992;304:165-8. 
 104.   Carstairs V. Deprivation indices: their interpretation and use in relation to health. Journal of 
Epidemiology and Community Health 1995;49:S3-S8. 
 105.   Talbot RJ. Underprivileged areas and health care planning: implications of use of Jarman 
indicators of urban deprivation. British Medical Journal 1991;302:383-6. 
 106.   Tunstall-Pedoe H, Woodward M. By neglecting deprivation, cardiovascular risk scoring will 
exacerbate social gradients in disease. Heart 2006;92:307-310  
 107.   Cummins SCJ, McKay L, and MacIntyre S. McDonalds Restaurants and Neighborhood 
Deprivation in Scotland and England. American journal of preventive medicine.  2005. 29(4), 
308-310.  
 108.   Smith GD, Whitley E, Dorling D, Gunnell D. Area based measures of social and economic 
circumstances: cause specific mortality patterns depend on the choice of index. Journal of 
Epidemiology and Community Health 2001;55:149-50. 
 109.   Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R. Choosing area 
based socioeconomic measures to monitor social inequalities in low birth weight and 
childhood lead poisoning: The Public Health Disparities Geocoding Project (US). Journal of 
Epidemiology and Community Health 2003;57:186-99. 
 110.   Diez Roux AV, Kiefe CI, Jacobs DR, Haan M, Jackson SA, Nieto FJ et al. Area Characteristics 
and Individual-Level Socioeconomic Position Indicators in Three Population-Based 
Epidemiologic Studies. Annals of Epidemiology. 2001 Vol. 11;6:395-405 
 111.   K E Pickett, M Pearl. Multilevel analyses of neighbourhood socioeconomic context and 
health outcomes: a critical review. J Epidemiol Community Health 2001;55:111-122 
  
 
107
 112.   G. Cesaroni, S. Farchi, M. Davoli, F. Forastiere, and C.A. Perucci. Individual and area-based 
indicators of socioeconomic status and childhood asthma. Eur Respir J 2003 22:619-624 
 113.   Pickett KE,.Pearl M. Multilevel analyses of neighbourhood socioeconomic context and health 
outcomes: a critical review. Journal of Epidemiology and Community Health 2001;55:111-22. 
 114.   MacIntyre S, Maciver S, Sooman A. Area, Class and Health: Should we be Focusing on 
Places or People? Journal of Social Policy 1993;22:213-34. 
 115.   MacIntyre S, Ellaway A, Cummins S. Place effects on health: how can we conceptualise, 
operationalise and measure them? Social Science & Medicine 2002;55:125-39. 
 116.   O’Campo P. Invited Commentary: Advancing Theory and Methods for Multilevel Models of 
Residential Neighborhoods and Health. Am.J.Epidemiol. 2003;157:9-13. 
 117.   Shukunami Ki, Nishijima K, Kotsuji F. PRETERM BIRTH: THE INTERACTION OF 
TRAFFIC-RELATED AIR POLLUTION WITH ECONOMIC HARDSHIP IN LOS 
ANGELES NEIGHBORHOODS. Am.J.Epidemiol. 2006;163:392-3. 
 118.   Smith GD, Hart C, Watt G, Hole D, Hawthorne V. Individual social class, area-based 
deprivation, cardiovascular disease risk factors, and mortality: the Renfrew and Paisley 
Study. Journal of Epidemiology and Community Health 1998;52:399-405. 
 119.   Marmot MG, Rose G, Shipley M, Hamilton PJ. Employment grade and coronary heart disease 
in British civil servants. Journal of Epidemiology and Community Health 1978;32:244-9. 
 120.   Diez-Roux AV, Nieto FJ, Caulfield L, Tyroler HA, Watson RL, Szklo M. Neighbourhood 
differences in diet: the Atherosclerosis Risk in Communities (ARIC) Study. Journal of 
Epidemiology and Community Health 1999;53:55-63. 
 121.   Reijneveld SA. Neighbourhood socioeconomic context and self reported health and smoking: 
a secondary analysis of data on seven cities. Journal of Epidemiology and Community Health 
2002;56:935-42. 
 122.   Diez Roux AV. Investigating Neighborhood and Area Effects on Health. Am J Public Health 
2001;91:1783-9. 
 123.   Cummins S, Curtis S, Diez-Roux AV, MacIntyre S. Understanding and representing place' in 
health research: A relational approach. Social Science & Medicine 2007;65:1825-38. 
 124.   Cubbin C, Winkleby M. Protective and Harmful Effects of Neighborhood-Level Deprivation 
on Individual-Level Health Knowledge, Behavior Changes, and Risk of Coronary Heart 
Disease Am. J. Epidemiol. 2005 162(6): 559-568  
 125.   Giles-Corti B, Donovan Robert J. The relative influence of individual, social and physical 
environment determinants of physical activity.  Social Science & Medicine Volume 54, 2002, 
Pages 1793-1812  
 126.   Geronimus AT. Invited Commentary: Using Area-based Socioeconomic Measures. Think 
Conceptually, Act Cautiously. Am.J.Epidemiol. 2006;164:835-40.  
 
108
 127.   Krieger, N Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R. Choosing area 
based socioeconomic measures to monitor social inequalities in low birth weight and 
childhood lead poisoning: The Public Health Disparities Geocoding Project (US). J 
Epidemiol Community Health 2003;57:186-199. 
 128.   Janssen I, Boyce WF, Simpson K, and Pickett W. Influence of individual- and area-level 
measures of socioeconomic status on obesity, unhealthy eating, and physical inactivity in 
Canadian adolescents. Am J Clin Nutr 2006 83: 1 139-145 
 129.   Amuzu A, Carson C, Watt HC, Lawlor DA, Ebrahim S. Influence of area and individual 
lifecourse deprivation on health behaviours: findings from the British Women's Heart and 
Health Study. Journal of Cardiovascular Risk 2009;16:169-73. 
 130.   Mitchell R, Popham F. Greenspace, urbanity and health: relationships in England. Journal of 
Epidemiology and Community Health 2007;61:681-3. 
 131.   Richardson EA,. Mitchell R. Gender differences in relationships between urban green space 
and health in the United Kingdom. Social Science & Medicine 2010;71:568-75. 
 132.   Mitchell, R. and Popham, F. Effect of exposure to natural environment on health inequalities: 
an observational population study. The Lancet, 2008. 372;9650:1655-1660.  
 133.   Beale N, Taylor G, Straker-Cook D. Does Council Tax Valuation Band (CTVB) correlate with 
Under-Privileged Area 8 (UPA8) score and could it be a better 'Jarman Index'? BMC Public 
Health 2001;1:13. 
 134.   Beale N, Taylor G, Straker-Cook D. Is Council Tax Valuation Band a predictor of mortality? 
BMC Public Health 2002;2:17-24. 
 135.   Beale N, Taylor G, Straker-Cook D, Gwynne M, Peart C. Council tax valuation band of patient 
residence and clinical contacts in a general practice. BJGP 2005;55:32-6. 
 136.   Beale N, Kane G, Gwynne M, Peart C, Taylor G, Herrick D et al. Council tax valuation band 
predicts breast feeding and socio-economic status in the ALSPAC study population. BMC 
Public Health 2006;6:5. 
 137.   Fone D, Dunstan F, Christie S, Jones A, West J, Webber M et al. Council tax valuation bands, 
socio-economic status and health outcome: a cross-sectional analysis from the Caerphilly 
Health and Social Needs Study. BMC Public Health 2006;6:115. 
 138.   Findlay I, Cunningham A, Krawczyk C, Garman E, Dochery P, Flood M. COUNCIL TAX 
BAND IS MORE SENSITIVE THAN INDEX OF MULTIPLE DEPRIVATION IN 
PREDICTING INCIDENCE OF CORONARY HEART DISEASE IN A DEPRIVED 
COMMUNITY Abstracts. Heart 2006;92:A4-A121. 
 139.   Lowther MA. Primary Prevention of Cardiovascular Disease In Scotland We Must Go 
Further. The Sottish Executive 2006. 
 140.   Currie CJ, Morgan CL, Peters JR. Patterns and costs of hospital care for coronary heart 
disease related and not related to diabetes. Heart 1997;78:544-9.  
 
109
 141.   Merzel C, D'Afflitti J. Reconsidering Community-Based Health Promotion: Promise, 
Performance, and Potential. American Journal of Public Health, 93(4), 557-574. 2003. 
 142.   Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk 
factor interventions for preventing coronary heart disease. BMJ 1997;314:1666. 
 143.   McQueen DV. Strengthening the evidence base for health promotion. Health Promot.Int. 
2001;16:261-8. 
 144.   Mackenzie M, O'Donnell C, Halliday E, Sridharan S, Platt S. Do health improvement 
programmes fit with MRC guidance on evaluating complex interventions? BMJ 
2010;340:c185. 
 145.   World Health Organization. HEALTH PROMOTION EVALUATION: 
RECOMMENDATIONS TO POLICY-MAKERS. WHO 1995. 
 146.   Puska P, Nissinen A, Tuomilehto J, Salonen JT, Koskela K, McAlister A et al. The Community-
Based Strategy to Prevent Coronary Heart Disease: Conclusions from the Ten Years of the 
North Karelia Project. Annual Review of Public Health 1985;6:147-93. 
 147.   Luepker RV, Murray DM, Jacobs DR, Jr., Mittelmark MB, Bracht N, Carlaw R et al. 
Community education for cardiovascular disease prevention: risk factor changes in the 
Minnesota Heart Health Program. Am J Public Health 1994;84:1383-93. 
 148.   Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, Hyde C. Community Programs 
for the Prevention of Cardiovascular Disease: A Systematic Review. Am.J.Epidemiol. 
2010;171. 
 149.   Pater C. The current status of primary prevention in coronary heart disease. Current 
Controlled Trials in Cardiovascular Medicine 2001;2:24-37. 
 150.   Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al. AHA Guidelines for 
Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel 
Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other 
Atherosclerotic Vascular Diseases. Circulation 2002;106:388-91. 
 151.   Puska P, Salonen JT, Nissinen A, Tuomilehto J, Vartiainen E, Korhonen H et al. Change in risk 
factors for coronary heart disease during 10 years of a community intervention programme 
(North Karelia project). British Medical Journal (Clinical research ed.) 1983;287:1840-4. 
 152.   Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR et al. Effects of 
intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac 
events in men and women with coronary artery disease. The Stanford Coronary Risk 
Intervention Project (SCRIP). Circulation 1994;89:975-90. 
 153.   FARQUHAR JW, Fortmann SP, MACCOBY NATH, HASKELL WL, WILLIAMS PT, FLORA 
JA et al. THE STANFORD FIVE-CITY PROJECT: DESIGN AND METHODS. 
Am.J.Epidemiol. 1985;122:323-34.  
 
110
 154.   Carlaw RW, Mittlemark MB, Bracht N, Luepker R. Organization for a Community 
Cardiovascular Health Program: Experiences from the Minnesota Heart Health Program. 
Health Education & Behavior 1984;11:243-52. 
 155.   Carleton RA, Lasater TM, Assaf AR, Feldman HA, McKinlay S. The Pawtucket Heart Health 
Program: community changes in cardiovascular risk factors and projected disease risk. Am 
J Public Health 1995;85:777-85. 
 156.   Lundvall H. Systematic review of CHD primary prevention, multiple risk factor population 
level interventions. Swedish National Institute for Public Health 1999. 
 157.    Puska, P. The North Karelia Project: 20 year results and experiences. National Public Health 
Institute  (Helsinki). 1995. ISBN 9515305497 
 158.   VARTIAINEN ERKK, PUSKA PEKK, JOUSILAHTI PEKK, KORHONEN HJ, 
TUOMILEHTO JAAK, NISSINEN AULI. Twenty-Year Trends in Coronary Risk Factors in 
North Karelia and in Other Areas of Finland. Int.J.Epidemiol. 1994;23:495-504. 
 159.   FARQUHAR JW, Fortmann SP, FLORA JA, TAYLOR CB, HASKELL WL, WILLIAMS PT et 
al. Effects of Communitywide Education on Cardiovascular Disease Risk Factors. JAMA 
1990;264:359-65. 
 160.   Fortmann SP, FLORA JA, Winkleby MA, Schooler C, TAYLOR CB, FARQUHAR JW. 
Community Intervention Trials: Reflections on the Stanford Five-City Project Experience. 
Am.J.Epidemiol. 1995;142:576-86. 
 161.   Luepker RV, Murray DM, Jacobs DR, Jr., Mittelmark MB, Bracht N, Carlaw R et al. 
Community education for cardiovascular disease prevention: risk factor changes in the 
Minnesota Heart Health Program. Am J Public Health 1994;84:1383-93. 
 162.   Carleton RA, Lasater TM, Assaf AR, Feldman HA, McKinlay S. The Pawtucket Heart Health 
Program: community changes in cardiovascular risk factors and projected disease risk. Am 
J Public Health 1995;85:777-85. 
 163.   Hoffmeister H, Mensink GBM, Stolzenberg H, Hoeltz J, Kreuter H, Laaser U et al. Reduction of 
Coronary Heart Disease Risk Factors in the German Cardiovascular Prevention Study. 
Preventive Medicine 1996;25:135-45. 
 164.   Gutzwiller F NBMJ. Community-based primary prevention of cardiovascular disease in 
Switzerland: methods and results of the National Research Program (NRP 1A). Prev 
Med.114(4):482-91. 1985. 
 165.   SHELLEY E, Daly L, COLLINS C, CHRISTIE M, CONROY R, GIBNEY M et al. 
Cardiovascular risk factor changes in the Kilkenny Health Project. European Heart Journal 
1995;16:752-60. 
 166.   SALONEN JT, PUSKA PEKK, KOTTKE TE, TUOMILEHTO JAAK. CHANGES IN 
SMOKING, SERUM CHOLESTEROL AND BLOOD PRESSURE LEVELS DURING A 
COMMUNITY-BASED CARDIOVASCULAR DISEASE PREVENTION PROGRAM. 
THE NORTH KARELIA PROJECT. Am.J.Epidemiol. 1981;114:81-94.  
 
111
 167.   Tretli S, Bjartveit K, Foss OP, Haider T, Lund-Larsen PG. Intervention on Cardiovascular 
Disease Risk Factors in Finnmark County: Changes after a Period of Three Years: The 
Cardiovascular Disease Study in Finnmark County, Norway. Scandinavian Journal of Public 
Health 1985;13:1-13. 
 168.   Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk 
factor interventions for preventing coronary heart disease. BMJ 1997;314:1666. 
 169.   Sanderson I. Evaluation, Policy Learning and Evidence-Based Policy Making. Public 
Administration 2002;80:1-22. 
 170.   von Eckardstein A. Is there a need for novel cardiovascular risk factors? Nephrol. Dial. 
Transplant. 2004;19:761-5. 
 171.   Yarnell JW. The PRIME study: classical risk factors do not explain the severalfold 
differences in risk of coronary heart disease between France and Northern Ireland. 
Prospective Epidemiological Study of Myocardial Infarction. QJM 1998;91:667-76. 
 172.   Wang, TJ. New cardiovascular risk factors exist, but are they clinically useful? Eur Heart J 
2008 29(4): 441-444 
 173.   Ridker PM, Stampfer MJ, Rifai N. Novel Risk Factors for Systemic Atherosclerosis: A 
Comparison of C-Reactive Protein, Fibrinogen, Homocysteine, Lipoprotein(a), and 
Standard Cholesterol Screening as Predictors of Peripheral Arterial Disease. JAMA 
2001;285:2481-5. 
 174.   OPARIL SUZA,.OBERMAN ALBE. Nontraditional Cardiovascular Risk Factors. The 
American Journal of the Medical Sciences 1999;317. 
 175.   American Heart Association http: www.americanheart.org/presenter.jhtml?identifier=4726. 
Risk Factors and Coronary Heart Disease, AHA Scientific Position. AHA 2010. 
 176.   Kaplan GA,.Keil JE. Socioeconomic factors and cardiovascular disease: a review of the 
literature. Circulation 1993;88:1973-98. 
 177.   Lindquist TL, Beilin LJ, Knuiman MW. Influence of Lifestyle, Coping, and Job Stress on 
Blood Pressure in Men and Women. Hypertension 1997;29:1-7. 
 178.   Lee YJ, Baek KW, Yun KW, Lim W, Lim W. The Associations of Coping Mechanism with 
Arterial Stiffness in Hwa-Byung Patients. Psychiatry Investig 2009;6:241-4. 
 179.   D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al. General 
Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study 
Circulation 2008, 117: 743-753  
 180.   Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to 
cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health 
Extended Cohort (SHHEC). Heart 2007;93:172-6.  
 
112
 181.   Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES et al. Lifetime Smoking 
Exposure Affects the Association of C-Reactive Protein with Cardiovascular Disease Risk 
Factors and Subclinical Disease in Healthy Elderly Subjects. Arterioscler Thromb Vasc Biol 
1997;17:2167-76. 
 182.   Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PWF et al. Prediction 
of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. 
Circulation 2006;113:791-8. 
 183.   Yusuf S, Reddy S, Ounpuu S, Anand S. Global Burden of Cardiovascular Diseases: Part I: 
General Considerations, the Epidemiologic Transition, Risk Factors, and Impact of 
Urbanization. Circulation 2001;104:2746-53. 
 184.   Greenland P, Gidding SS, Tracy RP. Commentary: Lifelong prevention of atherosclerosis: the 
critical importance of major risk factor exposures. Int.J.Epidemiol. 2002;31:1129-34. 
 185.   Canto JG, Iskandrian AE. Major Risk Factors for Cardiovascular Disease: Debunking the 
"Only 50%" Myth. JAMA 2003;290:947-9. 
 186.   Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman SM, Brener SJ et al. Prevalence of 
Conventional Risk Factors in Patients With Coronary Heart Disease. JAMA. 2003; 
290(7):898-904. 
 187.   Luepker RV, Rosamond WD, Murphy R, Sprafka JM, Folsom AR, McGovern PG et al. 
Socioeconomic status and coronary heart disease risk factor trends. The Minnesota Heart 
Survey. Circulation 1993;88:2172-9. 
 188.   Marmot MG, Bosma H, Hemingway H, Brunner E, Stansfeld S. Contribution of job control 
and other risk factors to social variations in coronary heart disease incidence. The Lancet 
1997;350:235-9. 
 189.   Everson, SA., Maty, SC., Lynch JW, Kaplan GA. Epidemiologic evidence for the relation 
between socioeconomic status and depression, obesity, and diabetes. Journal of 
psychosomatic research 53(4), 891-895. 10-1-2002.  
 190.   Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, Age, Cardiovascular Risk Factors, and 
Coronary Heart Disease : A Prospective Follow-Up Study of 14 786 Middle-Aged Men and 
Women in Finland. Circulation 1999;99:1165-72. 
 191.   Roeters van Lennep JE, Westerveld HT, Erkelens DW, and van der Wall EE. Risk factors for 
coronary heart disease: implications of gender. Cardiovasc Res (2002) 53(3): 538-549  
 192.   Stevenson, John C., Crook, David, and Godsland, Ian F. Influence of age and menopause on 
serum lipids and lipoproteins in healthy women. Atherosclerosis 98(1), 83-90. 1-4-1993.  
 193.   Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially 
modifiable risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. The Lancet 2004;364:937-52.  
 
113
 194.   Chaturvedi N, Stephenson JM, Fuller JH. The relationship between socioeconomic status and 
diabetes control and complications in the EURODIAB IDDM Complications Study. 
Diabetes Care 1996;19:423-30. 
 195.   Maty SC, Lynch JW, Raghunathan TE, Kaplan GA. Childhood Socioeconomic Position, 
Gender, Adult Body Mass Index, and Incidence of Type 2 Diabetes Mellitus Over 34 Years 
in the Alameda County Study. Am J Public Health 2008 98: 1486-1494  
 
 196.   Frederick, L. Brancati, Paul, K. Whelton, Lewis, H. Kuller, and Michael, J. Klag. Diabetes 
mellitus, race, and socioeconomic status a population-based study. Annals of epidemiology 
6(1), 67-73. 1-1-1996.  
 197.   Robbins JM, Vaccarino V, Zhang H, Kasl SV. Socioeconomic status and type 2 diabetes in 
African American and non-Hispanic white women and men: evidence from the Third 
National Health and Nutrition Examination Survey. Am J Public Health 2001;91:76-83. 
 198.   Goodman E, McEwen BS, Huang B, Dolan LM, Adler NE. Social Inequalities in Biomarkers 
of Cardiovascular Risk in Adolescence. Psychosom Med 2005;67:9-15. 
 199.   Marmot M, Shipley M, Hemingway H, Head J, Brunner E. Biological and behavioural 
explanations of social inequalities in coronary heart disease: the Whitehall II study. 
Diabetologia 2008;51:1980-8. 
 200.   Bartley M, Fitzpatrick R, Firth D, Marmot M. Social distribution of cardiovascular disease 
risk factors: change among men in England 1984-1993. Journal of Epidemiology and 
Community Health 2000;54:806-14. 
 201.   Sdringola S, Nakagawa K, Nakagawa Y, Yusuf SW, Boccalandro F, Mullani N et al. Combined 
intense lifestyle and pharmacologic lipid treatment further reduce coronary events and 
myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs 
in coronary artery disease. J Am Coll Cardiol 2003;41:263-72. 
 202.   McFadden E, Luben R, Wareham N, Bingham S, Khaw KT. Social Class, Risk Factors, and 
Stroke Incidence in Men and Women: A Prospective Study in the European Prospective 
Investigation Into Cancer in Norfolk Cohort. Stroke 2009;40:1070-7. 
 203.   Blane D, Hart CL, Davey Smith G, Gillis CR, Hole DJ, Hawthorne VM. Association of 
cardiovascular disease risk factors with socioeconomic position during childhood and 
during adulthood. BMJ 1996;313:1434-1438  
 204.   Lyratzopoulos G, Heller RF, Hanily M, Lewis PS. Deprivation status and mid-term change in 
blood pressure, total cholesterol and smoking status in middle life: a cohort study. Journal 
of Cardiovascular Risk 2007;14:844-50. 
 205.   Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB et al. HDL cholesterol 
and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. 
Circulation 1977;55:767-72. 
 206.   RAMSAY SE, MORRIS RW, Whincup PH, PAPACOSTA O, RUMLEY A, LENNON L et al. 
Socioeconomic inequalities in coronary heart disease risk in older age: contribution of  
 
114
established and novel coronary risk factors. Journal of Thrombosis and Haemostasis 
2009;7:1779-86. 
 207.   Minor D, Wofford M, Wyatt S. Does socioeconomic status affect blood pressure goal 
achievement? Current Hypertension Reports 2008;10:390-7. 
 208.   de Gaudemaris R, Lang T, Chatellier G, Larabi L, Lauwers-Cances V, Maitre A et al. 
Socioeconomic Inequalities in Hypertension Prevalence and Care: The IHPAF Study. 
Hypertension 2002;39:1119-25. 
 209.   Kershaw KN, Diez Roux AV, Carnethon M, Darwin C, Goff DC, Post W et al. Geographic 
Variation in Hypertension Prevalence Among Blacks and Whites: The Multi-Ethnic Study 
of Atherosclerosis. Am J Hypertens 2009;23:46-53. 
 210.   Luepker RV, Rosamond WD, Murphy R, Sprafka JM, Folsom AR, McGovern PG et al. 
Socioeconomic status and coronary heart disease risk factor trends. The Minnesota Heart 
Survey. Circulation 1993;88:2172-9. 
 211.   Ebrahimi M, Mansournia MA, Haghdoost AA, Abazari A, Alaeddini F, Mirzazadeh A et al. 
Social disparities in prevalence, treatment and control of hypertension in Iran: Second 
National Surveillance of Risk Factors of Noncommunicable Diseases, 2006. Journal of 
Hypertension 201;28. 
 212.   Ohlin B, Berglund G, Nilsson PM, Melander O. Job strain, job demands and adrenergic 
beta1-receptor-polymorphism: a possible interaction affecting blood pressure in men. 
Journal of Hypertension 2008;26. 
 213.   Barker DJP, Osmond C, Forsen TJ, Kajantie E, Eriksson JG. Maternal and Social Origins of 
Hypertension. Hypertension 2007;50:565-71. 
 214.   Hjermann I, Holme I, Velve Byer K, Leren P. EFFECT OF DIET AND SMOKING 
INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE : Report 
from the Oslo Study Group of a Randomised Trial in Healthy Men. The Lancet. 
1981;318:8259:1303-1310 
 215.   Stranges S, Bonner M, Fucci F, Cummings KM, Freudenheim JL, Dorn JM, et al. Lifetime 
Cumulative Exposure to Secondhand Smoke and Risk of Myocardial Infarction in Never 
Smokers: Results From the Western New York Health Study, 1995-2001. Arch Intern Med. 
2006;166(18):1961-1967. 
 216.   McFadden E, Luben R, Wareham N, Bingham S, Khaw KT. Social Class, Risk Factors, and 
Stroke Incidence in Men and Women: A Prospective Study in the European Prospective 
Investigation Into Cancer in Norfolk Cohort. Stroke 2009;40:1070-7. 
 217.   Cavelaars A E J M, Kunst AE, Geurts J J M, Crialesi R, Grötvedt L, Helmert U et al. 
Educational differences in smoking: international comparison. BMJ 2000;320:1102-1107 
 218.   Lyratzopoulos G, Heller RF, Hanily M, Lewis PS. Deprivation status and mid-term change in 
blood pressure, total cholesterol and smoking status in middle life: a cohort study. Journal 
of Cardiovascular Risk 2007;14:844-50.  
 
115
 219.   Yusuf S, Reddy S, Ounpuu S, Anand S. Global Burden of Cardiovascular Diseases: Part I: 
General Considerations, the Epidemiologic Transition, Risk Factors, and Impact of 
Urbanization. Circulation 2001;104:2746-53. 
 220.   Cummins S,.MacIntyre S. Food environments and obesity- neighbourhood or nation? 
Int.J.Epidemiol. 2006;35:100-4. 
 221.   Luepker RV, Rosamond WD, Murphy R, Sprafka JM, Folsom AR, McGovern PG et al. 
Socioeconomic status and coronary heart disease risk factor trends. The Minnesota Heart 
Survey. Circulation 1993;88:2172-9. 
 222.   Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose 
tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up 
of participants in the study of men born in 1913. BMJ (Clin Res Ed) 1984;288:1401-1404 
 223.   Everson, Susan A., Maty, Siobhan C., Lynch, John W., and Kaplan, George A. Epidemiologic 
evidence for the relation between socioeconomic status and depression, obesity, and 
diabetes. Journal of psychosomatic research 53(4), 891-895. 10-1-2002.  
 
 224.   Ljung R,.Hallqvist J. SOCIOECONOMIC POSITION, CLUSTERING OF RISK 
FACTORS, AND THE RISK OF MYOCARDIAL INFARCTION. Am J Public Health 
2007;97:1927-8. 
 225.   Wardle J, Waller J, Jarvis M. Sex Differences in the Association of Socioeconomic Status With 
Obesity. Am J Public Health 2002 92: 1299-1304 
  226.   Sargent RP, Shepard RM, Glantz SA. Reduced incidence of admissions for myocardial 
infarction associated with public smoking ban: before and after study. BMJ 2004;328:977-
980  
  227.    Capewell S, Graham H, Will Cardiovascular Disease Prevention Widen Health Inequalities? 
PLoS Med 7(8): e1000320. doi:10.1371/journal.pmed.1000320 
  228.    Rose G. The strategy of preventive medicine. 1992 Oxford: Oxford University Press. 
  229.      Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka L et al. Primary 
Prevention of Coronary Heart Disease: Guidance From Framingham : A Statement for 
Healthcare Professionals From the AHA Task Force on Risk Reduction. Circulation 97: 
1876-1887  
 230.   Lawson KD, Fenwick EAL, Pell ACH, Pell JP. Comparison of mass and targeted screening 
strategies for cardiovascular risk: simulation of the effectiveness, cost-effectiveness and 
coverage using a cross-sectional survey of 3921 people. Heart 2010;96:208-12. 
 231.   Mora S, Redberg RF, Sharrett AR, Blumenthal RS. Enhanced Risk Assessment in 
Asymptomatic Individuals With Exercise Testing and Framingham Risk Scores. Circulation 
2005;112:1566-72.  
 
116
 232.   Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to 
cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health 
Extended Cohort (SHHEC). Heart 2007;93:172-6. 
 233.   Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and 
validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: 
prospective open cohort study. BMJ 2007;335:136 
234.   Jackson R, Marshall R, Kerr A, Riddell T, Wells S. QRISK or Framingham for predicting 
cardiovascular risk? BMJ 2009;339 
235.   Marmot MG, Adelstein AM, Robinson N, Rose GA. Changing social-class distribution of 
heart disease. BMJ. 1978;2:1109-1112 
236.   O’Flaherty M, Bishop J, Redpath A, McLaughlin T, Murphy D, Chalmers J, Capewell S. 
Coronary heart disease mortality among young adults in Scotland in relation to social 
inequalities: time trend study. BMJ 2009;339 
237.  Leyland AH, Dundas R, McLoone P, Boddy FA. Inequalities in mortality in Scotland 1981-
2001. Glasgow: MRC Social and Public Health Sciences Unit. 2007  
238.  Levin KA, Leyland AH. Urban-rural inequalities in ischemic heart disease in Scotland, 1981-
1999. Am J Public Health. 2006;96:145-151.  
239.   Sundquist K, Malmstom M, Jahansson SE. Neighbourhood deprivation and incidence of 
coronary heart disease: a multilevel study of 2.6 million women and men in Sweden. J 
Epidemiol Community Health. 2004;58:71-77.  
240.   Thurston RC, Kubzansky LD, Kawachi I, Berkman LF. Is the association between 
socioeconomic position and coronary heart disease stronger in women than in men? Am J 
Epidemiol. 2005; 162:57-65 
241.   Capewell S, Flaherty M. Maximising secondary prevention therapies in patients with 
coronary heart disease. Heart 2008;94:8-9. 
 242.   Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K et al. Lipoprotein 
Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the 
Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60. 
 243.   Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G. Social deprivation and statin 
prescribing: a cross-sectional analysis using data from the new UK general practitioner 
'Quality and Outcomes Framework'. J Public Health 2007;29:40-7. 
 244.   Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT et al. Relationship Between 
Plasma LDL Concentrations During Treatment With Pravastatin and Recurrent Coronary 
Events in the Cholesterol and Recurrent Events Trial. Circulation 1998;97:1446-52. 
 245.   McAlister FA, Lawson FME, Teo KK, Armstrong PW. Randomised trials of secondary 
prevention programmes in coronary heart disease: systematic review. BMJ 2001;323:957-62.  
 
117
 246.   O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS, Jr. et al. An 
overview of randomized trials of rehabilitation with exercise after myocardial infarction. 
Circulation 1989;80:234-44. 
 247.   Unal B, Critchley JA, and Capewell S. Explaining the Decline in Coronary Heart Disease 
Mortality in England and Wales Between 1981 and 2000 Circulation 109: 1101-1107 
 248.   Moher M, Yudkin P, Wright L, Turner R, Fuller A, Schofield T, Mant D. Cluster randomised 
controlled trial to compare three methods of promoting secondary prevention of coronary 
heart disease in primary care. BMJ 2001;322:1338  
 249.   Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM. Secondary prevention in coronary 
heart disease: baseline survey of provision in general practice. BMJ 1998;316:1430-4. 
 250.   Dalal HM, Evans PH.  Achieving national service framework standards for cardiac 
rehabilitation and secondary prevention. BMJ 2003;326:481 
  251.   Lifestyle and risk factor management and use of drug therapies in coronary patients from 
15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. 
European Heart Journal 2001;22:554-72. 
 252.   EURO-ASPIRE Study Group. A European Society of Cardiology survey of secondary 
prevention of coronary heart disease. Eur Heart J 1997;18:1569-82. 
 253.   Downing A, Rudge G, Cheng Y, Tu YK, Keen J, Gilthorpe M. Do the UK government's new 
Quality and Outcomes Framework (QOF) scores adequately measure primary care 
performance? A cross-sectional survey of routine healthcare data. BMC Health Services 
Research 2007;7:166. 
 254.   Saxena S, Car J, Eldred D, Soljak M, Majeed A. Practice size, caseload, deprivation and 
quality of care of patients with coronary heart disease, hypertension and stroke in primary 
care: national cross-sectional study. BMC Health Services Research 2007;7:96. 
 255.   Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G. Social deprivation and statin 
prescribing: a cross-sectional analysis using data from the new UK general practitioner 
'Quality and Outcomes Framework'. J Public Health 2007;29:40-7. 
 256.   McLean G, Sutton M, Guthrie B. Deprivation and quality of primary care services: evidence 
for persistence of the inverse care law from the UK Quality and Outcomes Framework. 
Journal of Epidemiology and Community Health 2006;60:917-22. 
 257.   McLean G, Guthrie B, Sutton M. Differences in the quality of primary medical care for CVD 
and diabetes across the NHS: evidence from the quality and outcomes framework. BMC 
Health Services Research 2007;7:74. 
 258.   Campbell NC, Thain J, Dean HG, Ritchie LD, Rawles JM. Secondary prevention in coronary 
heart disease: baseline survey of provision in general practice. BMJ 1998;315:1430-4. 
 259.   Strong M, Maheswaran R, Radford J. Socioeconomic deprivation, coronary heart disease 
prevalence and quality of care: a practice-level analysis in Rotherham using data from the  
 
118
new UK general practitioner Quality and Outcomes Framework. J Public Health 
2006;28:39-42. 
 260.   Ashworth M, Medina J, Morgan M. Effect of social deprivation on blood pressure monitoring 
and control in England: a survey of data from the quality and outcomes framework. BMJ 
2008;337 
 261.   Cupples ME, Byrne MC, Smith SM, Leathem CS, Murphy AW. Secondary prevention of 
cardiovascular disease in different primary healthcare systems with and without pay-for-
performance. Heart 2008;94:1594-600. 
 262.   Hippisley-Cox J, Parker C, Coupland C, Vinogradova Y. Inequalities in the primary care of 
patients with coronary heart disease and serious mental health problems: a cross-sectional 
study. Heart 2007;93:1256-62. 
 263.   DeWilde S, Carey IM, Richards N, Whincup PH, Cook DG. Trends in secondary prevention of 
ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment. 
Heart 2008;94:83-8. 
 264.   Ramsay SE, Morris RW, Papacosta O, Lennon LT, Thomas MC, Whincup PH. Secondary 
prevention of coronary heart disease in older British men: extent of inequalities before and 
after implementation of the National Service Framework. J Public Health 2005;27:338-43. 
 265.   MacBride-Stewart SP, Elton R, Walley T. Do quality incentives change prescribing patterns 
in primary care? An observational study in Scotland. Fam.Pract. 2008;25:27-32. 
 266.   Capewell S, Unal B, Critchley JA, McMurray JJV. Over 20 000 avoidable coronary deaths in 
England and Wales in 2000: the failure to give effective treatments to many eligible 
patients. Heart 2006;92:521-3. 
 267.   Strong M, Maheswaran R, Radford J. Socioeconomic deprivation, coronary heart disease 
prevalence and quality of care: a practice-level analysis in Rotherham using data from the 
new UK general practitioner Quality and Outcomes Framework. J Public Health 
2006;28:39-42. 
 268.   Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D. Statin prescribing in 
Nottingham general practices: a cross-sectional study. J Public Health 1999;21:60-4. 
 269.   Ward PR, Noyce PR, St Leger AS. Are GP practice prescribing rates for coronary heart 
disease drugs equitable? A cross sectional analysis in four primary care trusts in England. 
Journal of Epidemiology and Community Health 2004;58:89-96. 
 270.   de Lusignan S, Belsey J, Hague N, Dhoul N, van Vlymen J. Audit-based education to reduce 
suboptimal management of cholesterol in primary care: a before and after study. J Public 
Health 2006;28:361-9. 
 271.   Ramsay SE, Morris RW, Papacosta O, Lennon LT, Thomas MC, Whincup PH. Secondary 
prevention of coronary heart disease in older British men: extent of inequalities before and 
after implementation of the National Service Framework. J Public Health 2005;27:338-43.  
 
119
 272.   Pears E, Hannaford PC, Taylor MW. Gender, age and deprivation differences in the primary 
care management of hypertension in Scotland: a cross-sectional database study. Fam.Pract. 
2003;20:22-31. 
 273.   Khunti K, Stone M, Paul S, Baines J, Gisborne L, Farooqi A et al. Disease management 
programme for secondary prevention of coronary heart disease and heart failure in 
primary care: a cluster randomised controlled trial. Heart 2007;93:1398-405. 
 274.   DeWilde S, Carey IM, Richards N, Whincup PH, Cook DG. Trends in secondary prevention of 
ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment. 
Heart 2008;94:83-8. 
 275.   Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J et al. Long-term 
compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after 
acute myocardial infarction. European Heart Journal 2006;27:1153-8. 
 276.   Clark AM,.Findlay IN. Improving evidence based cardiac care and policy implementation 
over the patient journey: the potential of coronary heart disease registers. Heart 
2005;91:1127-30. 
 277.   Simpson CR, Hannaford PC, Williams D. Evidence for inequalities in the management of 
coronary heart disease in Scotland. Heart 2005;91:630-4. 
 278.   British Medical Association. Quality and Outcomes Framework guidance for GMS contract 
2009/10 Delivering investment in general practice 
www.lmc.org.uk/downloadfile.aspx?path=/.../qofguidance200910mar09... NHS Employers, NHS 
Confederation 2009. 
 279.   British Medical Association.  GUIDANCE ON EXCEPTION REPORTING . NHS Employers, 
NHS Confederation 2006. 
 280.   Amos P. New GMS Contract QOF Implementation Dataset And Business Rules-Smoking 
Indicator Set 
http://www.wmrlmc.co.uk/gms2/information_technology/v12.0/smoking_ruleset_r4_v12_0.pdf. 
Department of Health 2008. 
 281.   SCIMP. SCIMP RECOMMENDED READ CODE FORMULARY(v2.0) : SEPT 2006 
http://filesdown.esecure.co.uk/NorthLancsPCT/SCIMPRecommendedReadCodelistv2_01.pdf_18
122008-1201-45.pdf. SCIMP 2006 2006. 
 282.   Amos P. New GP Contract Q&O Framework Implementation Dataset And Business Rules- 
Obesity Indicator Set 
http://www.pcc.nhs.uk/uploads/QOF/qof_bus_rules_v10/obesity_ruleset_v10.0.pdf. Department 
of Health 2007. 
 283.   Amos P. New GMS Contract QOF Implementation Dataset and Business Rules-Diabetes 
Mellitus Indicator Set 
http://www.pcc.nhs.uk/uploads/QOF/qof_bus_rules_v9/diabetes_ruleset_r4_v9.0.pdf. 
Department of Health 2008.  
 
120
 284.   MacDonald  J. New GMS Contract QOF Implementation Dataset and Business Rules-
Amendments - Version 16.0 
http://www.pcc.nhs.uk/uploads/QOF/Business%20Rules%20V16/amendments_-
_version_16_0_qof_rulesets.pdf. Department of Health 2009. 
 285.   Amos P. New GMS Contract QOF Implementation Dataset and Business Rules -Coronary 
Heart Disease Indicator Set. Department of Health 2009. 
 286.   BNF. British National Formulary http://bnf.org/bnf/index.htm. BNF 2010. 
 287.   Clark AM, Jamieson R, Findlay IN. Registries and Informed Consent. New England Journal of 
Medicine 2004;351:612-4. 
   288.    Hardin J, Hilbe J. Generalized Linear Models and Extensions, 2nd Edition. Stata Press 2007   
   289.   Lezzoni, L. Risk Adjustment for Measuring Health Care Outcomes, 3rd edition Academy 
Health,      2003 
   290.  The Scottish Government. The Scottish Health Survey: Topic Report: Obesity. 2011 accessed 
at   http://www.scotland.gov.uk/Publications/2011/10/25091711/18 November 2011. 